<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Probiotics for people with hepatic encephalopathy - Dalal, R - 2017 | Cochrane Library</title> <meta content="Probiotics for people with hepatic encephalopathy - Dalal, R - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008716.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Probiotics for people with hepatic encephalopathy - Dalal, R - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008716.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008716.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Probiotics for people with hepatic encephalopathy" name="citation_title"/> <meta content="Rohan Dalal" name="citation_author"/> <meta content="Westmead Hospital" name="citation_author_institution"/> <meta content="Richard G McGee" name="citation_author"/> <meta content="The Children's Hospital at Westmead" name="citation_author_institution"/> <meta content="dr.richardmcgee@gmail.com" name="citation_author_email"/> <meta content="Stephen M Riordan" name="citation_author"/> <meta content="The Prince of Wales" name="citation_author_institution"/> <meta content="Angela C Webster" name="citation_author"/> <meta content="The University of Sydney" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD008716.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/02/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008716.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008716.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008716.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cause of Death; Gastrointestinal Agents [*therapeutic use]; Hepatic Encephalopathy [mortality, *therapy]; Lactulose [*therapeutic use]; Probiotics [*therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008716.pub3&amp;doi=10.1002/14651858.CD008716.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008716\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008716\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","ru","ms","ja","hr","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008716.pub3",title:"Probiotics for people with hepatic encephalopathy",firstPublishedDate:"Feb 23, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato-Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008716.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008716.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008716.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008716.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008716.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008716.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008716.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008716.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008716.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008716.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7484 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008716.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-sec-0067"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-sec-0061"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/appendices#CD008716-sec-0072"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/table_n/CD008716StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/table_n/CD008716StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Probiotics for people with hepatic encephalopathy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/information#CD008716-cr-0004">Rohan Dalal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/information#CD008716-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Richard G McGee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/information#CD008716-cr-0006">Stephen M Riordan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008716.pub3/information#CD008716-cr-0007">Angela C Webster</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/information/en#CD008716-sec-0082">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 February 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008716.pub3">https://doi.org/10.1002/14651858.CD008716.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008716-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008716-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008716-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008716-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008716-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008716-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008716-abs-0001" lang="en"> <section id="CD008716-sec-0001"> <h3 class="title" id="CD008716-sec-0001">Background</h3> <p>Hepatic encephalopathy is a disorder of brain function as a result of liver failure or portosystemic shunt or both. Both hepatic encephalopathy (clinically overt) and minimal hepatic encephalopathy (not clinically overt) significantly impair patient’s quality of life and daily functioning, and represent a significant burden on healthcare resources. Probiotics are live micro‐organisms, which when administered in adequate amounts, may confer a health benefit on the host. </p> </section> <section id="CD008716-sec-0002"> <h3 class="title" id="CD008716-sec-0002">Objectives</h3> <p>To determine the beneficial and harmful effects of probiotics in any dosage, compared with placebo or no intervention, or with any other treatment for people with any grade of acute or chronic hepatic encephalopathy. This review did not consider the primary prophylaxis of hepatic encephalopathy. </p> </section> <section id="CD008716-sec-0003"> <h3 class="title" id="CD008716-sec-0003">Search methods</h3> <p>We searched The Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, conference proceedings, reference lists of included trials, and the World Health Organization International Clinical Trials Registry Platform until June 2016. </p> </section> <section id="CD008716-sec-0004"> <h3 class="title" id="CD008716-sec-0004">Selection criteria</h3> <p>We included randomised clinical trials that compared probiotics in any dosage with placebo or no intervention, or with any other treatment in people with hepatic encephalopathy. </p> </section> <section id="CD008716-sec-0005"> <h3 class="title" id="CD008716-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by The Cochrane Collaboration. We conducted random‐effects model meta‐analysis due to obvious heterogeneity of participants and interventions. We defined a P value of 0.05 or less as significant. We expressed dichotomous outcomes as risk ratio (RR) and continuous outcomes as mean difference (MD) with 95% confidence intervals (CI). </p> </section> <section id="CD008716-sec-0006"> <h3 class="title" id="CD008716-sec-0006">Main results</h3> <p>We included 21 trials with 1420 participants, of these, 14 were new trials. Fourteen trials compared a probiotic with placebo or no treatment, and seven trials compared a probiotic with lactulose. The trials used a variety of probiotics; the most commonly used group of probiotic was VSL#3, a proprietary name for a group of eight probiotics. Duration of administration ranged from 10 days to 180 days. Eight trials declared their funding source, of which six were independently funded and two were industry funded. The remaining 13 trials did not disclose their funding source. We classified 19 of the 21 trials at high risk of bias. </p> <p>We found no effect on all‐cause mortality when probiotics were compared with placebo or no treatment (7 trials; 404 participants; RR 0.58, 95% CI 0.23 to 1.44; low‐quality evidence). No‐recovery (as measured by incomplete resolution of symptoms) was lower for participants treated with probiotic (10 trials; 574 participants; RR 0.67, 95% CI 0.56 to 0.79; moderate‐quality evidence). Adverse events were lower for participants treated with probiotic than with no intervention when considering the development of overt hepatic encephalopathy (10 trials; 585 participants; RR 0.29, 95% CI 0.16 to 0.51; low‐quality evidence), but effects on hospitalisation and change of/or withdrawal from treatment were uncertain (hospitalisation: 3 trials, 163 participants; RR 0.67, 95% CI 0.11 to 4.00; very low‐quality evidence; change of/or withdrawal from treatment: 9 trials, 551 participants; RR 0.70, 95% CI 0.46 to 1.07; very low‐quality evidence). Probiotics may slightly improve quality of life compared with no intervention (3 trials; 115 participants; results not meta‐analysed; low‐quality evidence). Plasma ammonia concentration was lower for participants treated with probiotic (10 trials; 705 participants; MD ‐8.29 μmol/L, 95% CI ‐13.17 to ‐3.41; low‐quality evidence). There were no reports of septicaemia attributable to probiotic in any trial. </p> <p>When probiotics were compared with lactulose, the effects on all‐cause mortality were uncertain (2 trials; 200 participants; RR 5.00, 95% CI 0.25 to 102.00; very low‐quality evidence); lack of recovery (7 trials; 430 participants; RR 1.01, 95% CI 0.85 to 1.21; very low‐quality evidence); adverse events considering the development of overt hepatic encephalopathy (6 trials; 420 participants; RR 1.17, 95% CI 0.63 to 2.17; very low‐quality evidence); hospitalisation (1 trial; 80 participants; RR 0.33, 95% CI 0.04 to 3.07; very low‐quality evidence); intolerance leading to discontinuation (3 trials; 220 participants; RR 0.35, 95% CI 0.08 to 1.43; very low‐quality evidence); change of/or withdrawal from treatment (7 trials; 490 participants; RR 1.27, 95% CI 0.88 to 1.82; very low‐quality evidence); quality of life (results not meta‐analysed; 1 trial; 69 participants); and plasma ammonia concentration overall (6 trials; 325 participants; MD ‐2.93 μmol/L, 95% CI ‐9.36 to 3.50; very low‐quality evidence). There were no reports of septicaemia attributable to probiotic in any trial. </p> </section> <section id="CD008716-sec-0007"> <h3 class="title" id="CD008716-sec-0007">Authors' conclusions</h3> <p>The majority of included trials suffered from a high risk of systematic error (‘bias’) and a high risk of random error (‘play of chance’). Accordingly, we consider the evidence to be of low quality. Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development of overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but probiotics may lead to little or no difference in mortality. Whether probiotics are better than lactulose for hepatic encephalopathy is uncertain because the quality of the available evidence is very low. High‐quality randomised clinical trials with standardised outcome collection and data reporting are needed to further clarify the true efficacy of probiotics. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008716-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008716-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008716-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008716-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008716-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008716-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008716-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008716-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008716-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008716-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008716-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008716-abs-0002" lang="en"> <h3>Probiotics for people with hepatic encephalopathy</h3> <p><b>Why the review is important</b><br/>Hepatic encephalopathy is a disorder of brain function as a result of liver failure or portosystemic shunt or both. Both hepatic encephalopathy (clinically overt) and minimal hepatic encephalopathy (not clinically overt) significantly impair patient’s quality of life and daily functioning and represent a significant burden on healthcare resources. Probiotics are live micro‐organisms, which when administered in adequate amounts may confer a health benefit on the host. We searched and summarised randomised trials about the benefits and harms of any probiotic in any dosage, compared with placebo or no intervention, or with any other treatment for people with any grade of acute or chronic hepatic encephalopathy. </p> <p><b>Main findings</b><br/>The evidence is current to June 2016. Of the 21 included trials including 1420 participants, 14 trials compared a probiotic with placebo or no treatment and seven trials compared a probiotic with lactulose. The treatment duration of the trials ranged from 10 days to 180 days. </p> <p>Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development of overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but may lead to little or no difference in mortality. Probiotics may slightly improve quality of life when compared with no intervention; however, this conclusion is based on three trials with low‐quality evidence. Whether probiotics are better than lactulose for hepatic encephalopathy is uncertain because the quality of the available evidence was very low. There were no reports of septicaemia attributable to probiotic in any trial. There was no evidence of more adverse events with probiotics when compared to placebo or lactulose. </p> <p><b>Funding</b><br/>Eight trials declared their funding source, of which six were independently funded and two were industry funded. The remaining 13 trials did not disclose their funding source. </p> <p><b>Limitations of the review</b><br/>Many of the included trials suffered from a high risk of systematic error (‘bias’) and a high risk of random error (‘play of chance’). Accordingly, we consider the evidence to be of low quality. </p> <p><b>Conclusions</b><br/>Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development of overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but probiotics may lead to little or no difference in mortality. Whether probiotics are better than lactulose for hepatic encephalopathy is uncertain because the quality of the available evidence was very low. High‐quality randomised clinical trials with standardised outcome collection and data reporting are needed to further clarify the true efficacy of probiotics. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008716-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008716-sec-0067"></div> <h3 class="title" id="CD008716-sec-0068">Implications for practice</h3> <section id="CD008716-sec-0068"> <p>Due to the very low overall quality of the evidence, there is limited evidence for the use of probiotics compared with lactulose. Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development of overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but may lead to little or no difference in mortality. </p> </section> <h3 class="title" id="CD008716-sec-0069">Implications for research</h3> <section id="CD008716-sec-0069"> <p>Hepatic encephalopathy has a poor clinical outcome and is a significant burden on the healthcare system. Current treatment options are of limited efficacy. Probiotics represent an inexpensive alternative option; however, their benefits and harms are still uncertain, and many fundamental questions concerning their use remain. First, the benefits and harms of probiotics must be assessed in randomised clinical trials with low risk of systematic errors ('bias') and low risk of random errors ('play of chance'). Moreover, it is unknown whether all probiotics are of equal effectiveness or what dose or duration of probiotic therapy is necessary for treatment. It is also unknown whether colonisation though multiple dosing is necessary for benefit or if a single dose of probiotic suffices (<a href="./references#CD008716-bbs2-0308" title="McGeeR , O'ConnorPM , RussellD , DempseyEM , RyanAC , RossPR , et al. Prolonged faecal excretion following a single dose of probiotic in low birth weight infants. Acta Paediatrica2010;99(10):1587-8.">McGee 2010</a>). Future research should take these factors into account and consider alternative study designs; for example, factorial trials would allow multiple comparisons to be made in one trial. Future trials should also adhere to the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement, which makes recommendations for trials in people with hepatic encephalopathy (<a href="./references#CD008716-bbs2-0288" title="BajajJS , CordobaJ , MullenKD , AmodioP , ShawcrossDL , ButterworthRF , et al. Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Alimentary Pharmacology &amp; Therapeutics2011;33(7):739-47.">Bajaj 2011</a>), as well as guidelines for the nomenclature of hepatic encephalopathy (<a href="./references#CD008716-bbs2-0255" title="VilstrupH , AmodioP , BajajJ , CordobaJ , FerenciP , MullenKD , et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (Baltimore, Md.)2014;60:715-35. ">Vilstrup 2014</a>; <a href="./references#CD008716-bbs2-0281" title="AllampatiS , MullenKD . Nomenclature and definition of hepatic encephalopathy - An update. Clinical Liver Disease2015;5(3):68-70. [2046-2484]">Allampati 2015</a>). According to this new nomenclature, the term 'covert hepatic encephalopathy' is used to denote either 'minimal hepatic encephalopathy' or 'grade 1 hepatic encephalopathy' as per the West Haven criteria (<a href="./references#CD008716-bbs2-0294" title="ConnH , LeevyC , VlahcevicZ , RodgersJ , MaddreyW , SeeffL , et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology1977;72(4 (Pt 1)):573-83. [0016-5085]">Conn 1977</a>). As the trials included in this review typically pre‐date the development of this new nomenclature, we have continued to use the term 'minimal hepatic encephalopathy' where this has been historically applied by the original study authors to describe their study group, in order to precisely represent the participants enrolled in those particular studies. Furthermore, we have used the term ‘acute hepatic encephalopathy’ in our inclusion criteria as an inclusive term in order to select a broad range of studies. Any changes to the inclusion criteria based on the new nomenclature of ‘Type A hepatic encephalopathy’ should be considered for the next review update. The Human Microbiome Project is one important initiative that will likely contribute to a better understanding of the complex relationship between humans and microbes (<a href="./references#CD008716-bbs2-0325" title="TurnbaughPJ , LeyRE , HamadyM , Fraser-LiggettCM , KnightR , GordonJI . The human microbiome project. Nature2007;449(7164):804-10.">Turnbaugh 2007</a>). </p> <p>The high response in the control groups of this review reflects the natural history of hepatic encephalopathy, with its spontaneously fluctuating nature and possibility for spontaneous remission. Future trials should take this into account when assessing the efficacy of interventions. It is also important that those conducting trials also account for the time of day in which assessments are made. Consideration should be given to the type of placebo used, for example inactivated probiotic. All trials should at a minimum assess important outcomes such as mortality, quality of life, and adverse events. Trials should also be designed according to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Statement (<a href="http://www.spirit-statement.org/" target="_blank">www.spirit-statement.org/</a>) and reported following the CONSORT Statement (<a href="http://www.consort-statement.org/" target="_blank">www.consort-statement.org/</a>). </p> <p>Future systematic reviews on this topic ought to search also databases of regulatory authorities. Review authors should also use, for example, Trial Sequential Analysis to control risks of random errors. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008716-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008716-sec-0008"></div> <div class="table" id="CD008716-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Probiotic for people with hepatic encephalopathy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotic versus placebo or no intervention for people with hepatic encephalopathy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with hepatic encephalopathy<br/><b>Setting:</b> inpatients<br/><b>Intervention:</b> probiotic<br/><b>Comparison:</b> placebo/no intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with probiotic</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>All‐cause mortality</p> <p>(follow‐up: 2 weeks to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.58<br/>(0.23 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>404<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/>(12 to 73) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(6 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No‐recovery (incomplete resolution of clinical symptoms)</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.67<br/>(0.56 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>574<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>790 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>529 per 1000<br/>(442 to 624) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>877 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>588 per 1000<br/>(491 to 693) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events ‐ Overt hepatic encephalopathy</p> <p>(follow‐up: 2 weeks to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.29<br/>(0.16 to 0.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>585<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/>(27 to 86) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/>(27 to 86) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events ‐ Change of/or withdrawal from treatment</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.70<br/>(0.46 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>551<br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>204 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000<br/>(94 to 219) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/>(73 to 169) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma ammonia concentration (final and change scores) (μmol/L)</p> <p>(follow‐up: 1 month to 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean plasma ammonia concentration (final and change scores) (μmol/L) in the intervention group was 8.29 fewer (13.17 fewer to 3.41 fewer). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>705<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious concerns or two levels for very serious concerns of imprecision (based on few events and wide confidence intervals).<br/><sup>2</sup>Downgraded one level for serious concerns or two levels for very serious concerns of trials judged as at high risk of bias (most studies at high risk of bias).<br/><sup>3</sup>Downgraded one level for serious concerns or two levels for very serious concerns of inconsistency of the outcomes in effects. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008716-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Probiotics for people with hepatic encephalopathy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotic versus lactulose for people with hepatic encephalopathy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with hepatic encephalopathy<br/><b>Setting:</b> inpatients<br/><b>Intervention:</b> probiotic<br/><b>Comparison:</b> lactulose </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lactulose</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with probiotic</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>(follow‐up: 1 month to 2 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.00<br/>(0.25 to 102.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>200<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No‐recovery (incomplete resolution of clinical symptoms)</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.01<br/>(0.85 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>430<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>521 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>526 per 1000<br/>(443 to 630) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>505 per 1000<br/>(425 to 605) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events ‐ Overt hepatic encephalopathy</p> <p>(follow‐up: 1 to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.17<br/>(0.63 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>420<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000<br/>(51 to 177) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1000<br/>(38 to 129) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events ‐ Change of/or withdrawal from treatment</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.27<br/>(0.88 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>490<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000<br/>(141 to 291) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000<br/>(101 to 208) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>It is uncertain whether probiotics improve quality of life because the available evidence is of very low quality. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma ammonia concentration (final and change scores) (μmol/L)</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean plasma ammonia concentration (final and change scores) (μmol/L) in the intervention group was 2.93 fewer (9.36 fewer to 3.5 more). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one for serious concerns or two levels for very serious concerns of imprecision (small samples, very few events, and wide confidence intervals).<br/><sup>2</sup>Downgraded one level for serious concerns or two levels for very serious concerns of trials judged as at high risk of bias (majority of studies at high risk of bias).<br/><sup>3</sup>Downgraded one level for serious imprecision (95% CI includes null effects).<br/><sup>4</sup>Downgraded one level for serious concerns or two levels for very serious concerns of inconsistency in results. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008716-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008716-sec-0009"></div> <section id="CD008716-sec-0010"> <h3 class="title" id="CD008716-sec-0010">Description of the condition</h3> <p>Hepatic encephalopathy (also known as portosystemic encephalopathy) is a reversible neuropsychiatric disorder seen in the context of either acute or chronic liver failure or portosystemic shunting, or both (<a href="./references#CD008716-bbs2-0296" title="FerenciP , LockwoodA , MullenK , TarterR , WeissenbornK , BleiAT . Hepatic encephalopathy - Definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology (Baltimore, Md.)2002;35:716-21.">Ferenci 2002</a>). Hepatic encephalopathy is characterised by complex cognitive dysfunction, which is independent of sleep dysfunction or problems with overall intelligence (<a href="./references#CD008716-bbs2-0291" title="BleiAT , CórdobaJ . Hepatic encephalopathy. American Journal of Gastroenterology2001;96:1968-76.">Blei 2001</a>). Minimal hepatic encephalopathy is a milder form of the same condition, which does not have obvious clinical signs (<a href="./references#CD008716-bbs2-0239" title="StewartCA , SmithGE . Minimal hepatic encephalopathy. Nature Clinical Practice. Gastroenterology &amp; Hepatology2007;4(12):677-85. ">Stewart 2007</a>; <a href="./references#CD008716-bbs2-0288" title="BajajJS , CordobaJ , MullenKD , AmodioP , ShawcrossDL , ButterworthRF , et al. Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Alimentary Pharmacology &amp; Therapeutics2011;33(7):739-47.">Bajaj 2011</a>). The onset of hepatic encephalopathy indicates a poor prognostic outcome. It may also reduce quality of life and level of daily functioning (<a href="./references#CD008716-bbs2-0300" title="GroenewegM , QueroJC , De BruijnI , HartmannIJC , Essink-botM , HopWCJ , et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology (Baltimore, Md.)1998;28:45-9.">Groeneweg 1998</a>; <a href="./references#CD008716-bbs2-0287" title="ArguedasMR , DeLawrenceTG , McGuireBM . Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Digestive Diseases and Sciences2003;48:1622-6.">Arguedas 2003</a>). The pathophysiology of hepatic encephalopathy is still uncertain, but the prevailing assumption is that different toxins, such as false neurotransmitters, natural benzodiazepines, short‐chain fatty acids, and mercaptans enhance the negative effects of ammonia on the level of consciousness (<a href="./references#CD008716-bbs2-0293" title="ButterworthRF , GiguèreJF , MichaudJ , LavoieJ , LayrarguesGP . Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Molecular and Chemical Neuropathology1987;6:1-12.">Butterworth 1987</a>; <a href="./references#CD008716-bbs2-0291" title="BleiAT , CórdobaJ . Hepatic encephalopathy. American Journal of Gastroenterology2001;96:1968-76.">Blei 2001</a>; <a href="./references#CD008716-bbs2-0326" title="VaqueroJ , ChungC , CahillME , BleiAT . Pathogenesis of hepatic encephalopathy in acute liver failure. Seminars in Liver Disease2003;23:259-69.">Vaquero 2003</a>). Current therapeutic options include intensive supportive care, identification and correction of the precipitating causes, tailored dietary restrictions, non‐absorbable disaccharides, L‐ornithine L‐aspartate, and/or oral antibiotics (<a href="./references#CD008716-bbs2-0311" title="RiordanSM , WilliamsR . Treatment of hepatic encephalopathy. New England Journal of Medicine1997;337:473.">Riordan 1997</a>; <a href="./references#CD008716-bbs2-0291" title="BleiAT , CórdobaJ . Hepatic encephalopathy. American Journal of Gastroenterology2001;96:1968-76.">Blei 2001</a>; <a href="./references#CD008716-bbs2-0282" title="Als-NielsenB , KoretzRL , GluudLL , GluudC . Branched-chain amino acids for hepatic encephalopathy. Cochrane Database of Systematic Reviews2003, Issue 1. Art. No: CD001939. [DOI: 10.1002/14651858.CD001939]">Als‐Nielsen 2003</a>; <a href="./references#CD008716-bbs2-0283" title="Als-NielsenB , GluudLL , GluudC . Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews2004, Issue 2. Art. No: CD002798. [DOI: 10.1002/14651858.CD002798.pub2]">Als‐Nielsen 2004a</a>; <a href="./references#CD008716-bbs2-0284" title="Als-NielsenB , GluudLL , GluudC . Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database of Systematic Reviews2004, Issue 2. Art. No: CD003044. [DOI: 10.1002/14651858.CD003044.pub2]">Als‐Nielsen 2004b</a>; <a href="./references#CD008716-bbs2-0285" title="Als-NielsenB , GluudLL , GluudC . Dopaminergic agonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD003047. [DOI: 10.1002/14651858.CD003047.pub2]">Als‐Nielsen 2004c</a>; <a href="./references#CD008716-bbs2-0303" title="JiangQ , JiangXH , ZhengMH , ChenYP . l ornithine l aspartate in the management of hepatic encephalopathy: a meta analysis. Journal of Gastroenterology and Hepatology2009;24(1):9-14.">Jiang 2009</a>). </p> </section> <section id="CD008716-sec-0011"> <h3 class="title" id="CD008716-sec-0011">Description of the intervention</h3> <p>Probiotics are live micro‐organisms, which when administered in adequate amounts may confer a health benefit on the host (<a href="./references#CD008716-bbs2-0317" title="SchrezenmeirJ , deVreseM . Probiotics, prebiotics, and synbiotics - approaching a definition. American Journal of Clinical Nutrition2001;73:361S.">Schrezenmeir 2001</a>). However, the dose needed to confer a health benefit is unknown for many conditions. Probiotics commonly come from two groups of bacteria, <i>Lactobacillus</i> or <i>Bifidobacterium</i> . Within each group, there are different species (e.g. <i>Lactobacillus acidophilus</i> and <i>Bifidobacterium bifidus</i> ), and within each species, different strains (or varieties). A few common probiotics, such as <i>Saccharomyces boulardii</i>, are yeasts, which are different from bacteria. Therapeutic effects may be strain specific, and so caution must be exerted in generalising results from one species to another. While probiotics are generally considered safe, adverse events have been attributed to their use (<a href="./references#CD008716-bbs2-0290" title="BesselinkMGH , vanSantvoortHC , BuskensE , BoermeesterMA , vanGoorH , TimmermanHM , et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet2008;371(9613):651-9.">Besselink 2008</a>). </p> </section> <section id="CD008716-sec-0012"> <h3 class="title" id="CD008716-sec-0012">How the intervention might work</h3> <p>There is some evidence for an alteration in the composition of the gastrointestinal bacterial flora of people with liver disease (<a href="./references#CD008716-bbs2-0312" title="RolfeRD . The role of probiotic cultures in the control of gastrointestinal health. Journal of Nutrition2000;130:396.">Rolfe 2000</a>). Modulation of the gut microbiota is an important aspect of current therapy; the current conventional treatment option of the broad‐spectrum antibiotic rifaxamin is minimally absorbed and targets gram‐negative and gram‐positive enteric bacteria. Similarly, in addition to the osmotic effect of lactulose, which encourages removal of toxic metabolic products such as ammonia, it is also known to have a bifidogenic effect (<a href="./references#CD008716-bbs2-0295" title="De PreterV , VanhoutteT , HuysG , SwingsJ , RutgeertsP , VerbekeK . Effect of lactulose and Saccharomyces boulardii administration on the colonic urea-nitrogen metabolism and the bifidobacteria concentration in healthy human subjects. Alimentary Pharmacology &amp; Therapeutics2006;23(7):963-74. [0269-2813: (Print)]">De Preter 2006</a>; <a href="./references#CD008716-bbs2-0289" title="BassNM , MullenKD , SanyalA , PoordadF , NeffG , LeevyCB , et al. Rifaximin treatment in hepatic encephalopathy. New England Journal of Medicine2010;362(12):1071-81. [0028-4793]">Bass 2010</a>). Amongst other potential reasons, one rationale behind the use of probiotics for hepatic encephalopathy is to reduce the prevalence of harmful ammonia‐producing bacteria in the gastrointestinal system. Probiotics are thought to reduce blood ammonia levels by several mechanisms including decreasing bacterial urease activity, decreasing ammonia absorption by decreasing pH, decreasing intestinal permeability, and improving nutritional status of gut epithelium (<a href="./references#CD008716-bbs2-0191" title="PohZ , ChangPEJ . A current review of the diagnostic and treatment strategies of hepatic encephalopathy. International Journal of Hepatology2012;2012:480309. ">Poh 2012</a>). </p> </section> <section id="CD008716-sec-0013"> <h3 class="title" id="CD008716-sec-0013">Why it is important to do this review</h3> <p>Hepatic encephalopathy significantly impairs patient’s quality of life and daily functioning, job performance, and overall mortality (<a href="./references#CD008716-bbs2-0300" title="GroenewegM , QueroJC , De BruijnI , HartmannIJC , Essink-botM , HopWCJ , et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology (Baltimore, Md.)1998;28:45-9.">Groeneweg 1998</a>; <a href="./references#CD008716-bbs2-0287" title="ArguedasMR , DeLawrenceTG , McGuireBM . Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Digestive Diseases and Sciences2003;48:1622-6.">Arguedas 2003</a>; <a href="./references#CD008716-bbs2-0322" title="StintonLM , JayakumarS . Minimal hepatic encephalopathy. Canadian Journal of Gastroenterology2013;27(10):572-4. [0835-7900]">Stinton 2013</a>). Caring for and treating patients with hepatic encephalopathy is a significant burden on the healthcare system. In 2005, hepatic encephalopathy cost the US healthcare system an estimated USD 4676.7 million, increasing to USD 7244.7 million in 2009 (<a href="./references#CD008716-bbs2-0321" title="StepanovaM , MishraA , VenkatesanC , YounossiZM . In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clinical Gastroenterology and Hepatology2012;10(9):1034-41.e1. [1542-3565]">Stepanova 2012</a>). Previous Cochrane Hepato‐Biliary Group systematic reviews have only shown moderate, and in some cases no benefit for current or proposed therapies for hepatic encephalopathy, which include non‐absorbable disaccharides, oral antibiotics, branched‐chain amino acids, and dopamine (<a href="./references#CD008716-bbs2-0282" title="Als-NielsenB , KoretzRL , GluudLL , GluudC . Branched-chain amino acids for hepatic encephalopathy. Cochrane Database of Systematic Reviews2003, Issue 1. Art. No: CD001939. [DOI: 10.1002/14651858.CD001939]">Als‐Nielsen 2003</a>; <a href="./references#CD008716-bbs2-0283" title="Als-NielsenB , GluudLL , GluudC . Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews2004, Issue 2. Art. No: CD002798. [DOI: 10.1002/14651858.CD002798.pub2]">Als‐Nielsen 2004a</a>; <a href="./references#CD008716-bbs2-0284" title="Als-NielsenB , GluudLL , GluudC . Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database of Systematic Reviews2004, Issue 2. Art. No: CD003044. [DOI: 10.1002/14651858.CD003044.pub2]">Als‐Nielsen 2004b</a>; <a href="./references#CD008716-bbs2-0285" title="Als-NielsenB , GluudLL , GluudC . Dopaminergic agonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD003047. [DOI: 10.1002/14651858.CD003047.pub2]">Als‐Nielsen 2004c</a>; <a href="./references#CD008716-bbs2-0304" title="JunkerAE , Als-NielsenB , GluudC , GluudLL . Dopamine agents for hepatic encephalopathy. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD003047. [DOI: 10.1002/14651858.CD003047.pub3]">Junker 2014</a>; <a href="./references#CD008716-bbs2-0297" title="GluudLL , DamG , LesI , CórdobaJ , MarchesiniG , BorreM , et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD001939. [DOI: 10.1002/14651858.CD001939.pub3]">Gluud 2015</a>). Based on a preliminary analysis, it is estimated that the literature on probiotics in hepatic encephalopathy has doubled since this systematic review was last published in 2011, hence this update will improve the evidence base on the use of probiotics in hepatic encephalopathy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008716-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008716-sec-0014"></div> <p>To determine the beneficial and harmful effects of probiotics in any dosage, compared with placebo or no intervention or with any other treatment for people with any grade of acute or chronic hepatic encephalopathy. This review did not consider the primary prophylaxis of hepatic encephalopathy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008716-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008716-sec-0015"></div> <section id="CD008716-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008716-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised trials that compared probiotics with placebo or no intervention, or with any other treatment for people with hepatic encephalopathy. We applied no restrictions on language of publication, publication date, or publication status. We excluded quasi‐randomised trials. </p> </section> <section id="CD008716-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD008716-sec-0019"> <h5 class="title">Inclusion criteria</h5> <p>We included all people with any grade of acute or chronic hepatic encephalopathy in connection with acute and chronic liver disease as well as acute hepatic failure, no matter the aetiology of liver disease or factors precipitating the hepatic encephalopathy. </p> </section> <section id="CD008716-sec-0020"> <h5 class="title">Exclusion criteria</h5> <p>We excluded trials with participants in whom a diagnosis of hepatic encephalopathy was not confirmed, that is where altered mental status or cognitive function was not confirmed by a standardised neuropsychological assessment. Where co‐interventions such as medication were being administered, they had to be administered equally across the relevant intervention groups of the trial so that fair comparisons could be made. </p> </section> </section> <section id="CD008716-sec-0021"> <h4 class="title">Types of interventions</h4> <p>Any probiotic at any dose for any duration. Additional co‐interventions were allowed if received by all trial intervention groups and deemed sufficiently similar across trial groups. Where synbiotics were used (a combination of a prebiotic and a probiotic; a prebiotic is a substance that stimulates the growth of probiotics), the control group must have received a similar prebiotic to be included in the review, such that across trial groups the difference in intervention(s) was probiotic alone. For example, where probiotic and lactulose were compared to antibiotic plus lactulose, the comparison would have been probiotics versus antibiotic. If a trial compared probiotics and prebiotics versus prebiotics, the trial would have been considered a probiotic versus placebo trial, as the difference between the two groups would have been probiotic alone. </p> </section> <section id="CD008716-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>We assessed all outcomes at time points reported by the authors, but, where possible, also summarised at one, two, three, six months, and one year. </p> <section id="CD008716-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008716-list-0001"> <li> <p>All‐cause mortality: number of participants dead.</p> </li> <li> <p>Number of participants who did not recover from hepatic encephalopathy (defined as incomplete resolution of clinical symptoms). We considered an individual to be 'completely resolved' if he or she was not in a state of hepatic encephalopathy based on the trial’s definition of hepatic encephalopathy used in the inclusion process. </p> </li> <li> <p>Adverse events: number and type of adverse events, defined as participants with any untoward medical occurrence. We summarised adverse events that led to treatment discontinuation and those that did not lead to treatment discontinuation separately. We defined serious adverse events according to the International Conference on Harmonisation (ICH) guidelines (<a href="./references#CD008716-bbs2-0302" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1. Philadelphia (PA): Barnett International/PAREXEL, 1997.">ICH‐GCP 1997</a>), as any event that led to death, was life‐threatening, required inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability, and any important medical event that may have jeopardised the patient or required intervention to prevent it. We considered all other adverse events as non‐serious. </p> </li> <li> <p>Quality of life: as measured by the 36‐Item Short Form Health Survey (SF‐36) or other similar validated scales, such as the Sickness Impact Profile (SIP) (<a href="./references#CD008716-bbs2-0292" title="BrazierJE , HarperR , JonesNMB , O'CathainA , ThomasKJ , UsherwoodT , et al. Validating the SF-36® Health Survey Questionnaire: new outcome measure for primary care. BMJ (Clinical Research Ed.)1992;305:160-4.">Brazier 1992</a>; <a href="./references#CD008716-bbs2-0327" title="WareJE , KosinskiM , KellerSK . SF-36® Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute, 1994.">Ware 1994</a>). </p> </li> </ol> </p> </section> <section id="CD008716-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008716-list-0002"> <li> <p>Change of or withdrawal from treatment: number of participants who changed/withdrew from their allocated treatment regimen. </p> </li> <li> <p>Sepsis: number of participants with one or more episodes of sepsis (confirmed by a positive blood culture). </p> </li> <li> <p>Change in plasma ammonia concentration.</p> </li> <li> <p>Duration of stay in hospital: measured in days.</p> </li> </ol> </p> </section> </section> </section> <section id="CD008716-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008716-sec-0026"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched The Cochrane Hepato‐Biliary Group Controlled Trials Register (<a href="./references#CD008716-bbs2-0298" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 5. Art. No.: LIVER.">Gluud 2016</a>), The Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE Ovid, Embase Ovid, and Science Citation Index Expanded (Web of Science) (<a href="./references#CD008716-bbs2-0313" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591-603.">Royle 2003</a>) all on the 14th of June 2016. The search strategies with the time spans of the searches are given in <a href="./appendices#CD008716-sec-0073">Appendix 1</a>. The search filter for randomised trials in MEDLINE (OvidSP) was created by <a href="./references#CD008716-bbs2-0306" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>, and the search filter for randomised trials in Embase (OvidSP) was created by <a href="./references#CD008716-bbs2-0319" title="SharonSLW , WilczynskiNL , HaynesRB . Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. Journal of the Medical Library Association2006;94:41-7.">Sharon 2006</a>. </p> <p>We also searched the World Health Organization International Clinical Trial Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>) for ongoing and unpublished trials up to June 2016 using an advanced search for the condition 'hepatic encephalopathy' and intervention 'probiotic', and using an advanced search for the condition 'hepatic encephalopathy'. As a quality check, we searched the ClinicalTrials.gov database (<a href="https://clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov/ct2/home</a>) in September 2016, even though ClinicalTrials.gov is included as one of the registers within the WHO ICTRP portal. </p> </section> <section id="CD008716-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We handsearched the proceedings of three relevant conferences:</p> <p> <ol id="CD008716-list-0003"> <li> <p>American Association for the Study of Liver Disease (AASLD) from 2005 to 2014;</p> </li> <li> <p>European Association for the Study of the Liver (EASL) from 2005 to 2014;</p> </li> <li> <p>Digestive Diseases Week (DDW) from 2005 to 2014, using the keywords 'hepatic encephalopathy', 'probiotic', 'bifidobacterium', 'lactobacillus', and 'liver disease'. </p> </li> </ol> </p> <p>We identified further trials through reference lists of relevant articles and by contacting content experts and authors of included trials. We applied no date or language restrictions. We translated non‐English language articles using Google Translate (<a href="https://translate.google.com.au/" target="_blank">translate.google.com.au/</a>). Mandarin translations were provided by Sunny Wu. </p> </section> </section> <section id="CD008716-sec-0028"> <h3 class="title" id="CD008716-sec-0028">Data collection and analysis</h3> <section id="CD008716-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Working independently, three review authors conducted trial selection and data extraction. None of the review authors was blinded to journal or author names. Disagreements were resolved by consensus. </p> </section> <section id="CD008716-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following information using a standardised data extraction form.</p> <p> <ul id="CD008716-list-0004"> <li> <p>General information: author(s), title, source, contact address, year of trial, country of trial, language of publication, year of publication. </p> </li> <li> <p>Trial characteristics: design (randomised clinical trial), randomisation method, manner of recruitment, sampling method, duration of intervention period, length of follow‐up, reason for and number of dropouts and withdrawals, adverse events. </p> </li> <li> <p>Participants: baseline characteristics of participants in treatment groups such as sex, age, prevalence of comorbidities (e.g. diabetes), inclusion and exclusion trial criteria. </p> </li> <li> <p>Trial setting: e.g. inpatient/outpatient department, emergency department.</p> </li> <li> <p>Detailed description of both the intervention and the comparison intervention, type, dose, and duration of probiotic(s). </p> </li> <li> <p>Outcomes: specific outcome reported, assessment instrument used, scoring range where appropriate. </p> </li> <li> <p>Any co‐interventions.</p> </li> </ul> </p> <p>We entered data into Review Manager 5 software and checked the data for accuracy (<a href="./references#CD008716-bbs2-0310" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2011</a>). </p> </section> <section id="CD008716-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We followed the instructions given in the <i>Cochrane Handbook for Systematic Reviews of Intervention</i> (<a href="./references#CD008716-bbs2-0301" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>) and the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD008716-bbs2-0298" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 5. Art. No.: LIVER.">Gluud 2016</a>). Methodological quality was defined as the confidence that the design and the report of the randomised clinical trial would restrict bias in the comparison of the treatment groups (<a href="./references#CD008716-bbs2-0309" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352:609-13.">Moher 1998</a>). According to empirical evidence (<a href="./references#CD008716-bbs2-0318" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD008716-bbs2-0309" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352:609-13.">Moher 1998</a>; <a href="./references#CD008716-bbs2-0305" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>; <a href="./references#CD008716-bbs2-0329" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.)2008;336:601-5.">Wood 2008</a>; <a href="./references#CD008716-bbs2-0307" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub2]">Lundh 2012</a>; <a href="./references#CD008716-bbs2-0315" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1-82.">Savović 2012</a>; <a href="./references#CD008716-bbs2-0316" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savović 2012a</a>), we assessed the risk of bias of the trials using the following 'Risk of bias' domains. </p> <section id="CD008716-sec-0032"> <h5 class="title">Sequence generation</h5> <p> <ul id="CD008716-list-0005"> <li> <p>Low risk of bias: the method used was either adequate (e.g. computer‐generated random numbers, table of random numbers) or unlikely to introduce bias. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether the method used was likely to introduce confounding. </p> </li> <li> <p>High risk of bias: the method used was not best practise for randomisation.</p> </li> </ul> </p> </section> <section id="CD008716-sec-0033"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD008716-list-0006"> <li> <p>Low risk of bias: the method used (e.g. central allocation) was unlikely to induce bias on the final observed effect. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether the method used was likely to induce bias on the estimate of effect. </p> </li> <li> <p>High risk of bias: the method used (e.g. open random allocation schedule) was likely to induce bias on the final observed effect. </p> </li> </ul> </p> </section> <section id="CD008716-sec-0034"> <h5 class="title">Blinding of participants</h5> <p> <ul id="CD008716-list-0007"> <li> <p>Low risk of bias: blinding was performed adequately, or the outcome was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether the type of blinding used was likely to induce bias on the effect. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the outcome was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD008716-sec-0035"> <h5 class="title">Blinding of personnel</h5> <p> <ul id="CD008716-list-0008"> <li> <p>Low risk of bias: blinding was performed adequately, or the outcome was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether the type of blinding used was likely to induce bias on the effect. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the outcome was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD008716-sec-0036"> <h5 class="title">Blinding of outcome assessors</h5> <p> <ul id="CD008716-list-0009"> <li> <p>Low risk of bias: blinding was performed adequately, or the outcome measurement was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether the type of blinding used was likely to induce bias on the estimate of effect. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the outcome measurement was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD008716-sec-0037"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD008716-list-0010"> <li> <p>Low risk of bias: the underlying reasons for missing data were unlikely to cause treatment effects to depart from plausible values, or appropriate methods were employed to handle missing data. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether the missing‐data mechanism in combination with the method used to handle missing data was likely to induce bias on the estimate of effect. </p> </li> <li> <p>High risk of bias: the crude estimate of effects (e.g. complete‐case estimate) was clearly biased due to the underlying reasons for missing data, and the methods used to handle missing data were unsatisfactory. </p> </li> </ul> </p> </section> <section id="CD008716-sec-0038"> <h5 class="title">Selective outcome reporting</h5> <p> <ul id="CD008716-list-0011"> <li> <p>Low risk of bias: the trial protocol was available, or the study author provided further information about prespecified outcomes and all of the trial's prespecified outcomes that were of interest in the review were reported or similar. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether the magnitude and direction of the observed effect were related to selective outcome reporting. </p> </li> <li> <p>High risk of bias: not all of the trial's prespecified primary outcomes were reported or similar. </p> </li> </ul> </p> </section> <section id="CD008716-sec-0039"> <h5 class="title">Other bias</h5> <p> <ul id="CD008716-list-0012"> <li> <p>Low risk of bias: the trial was independently funded, e.g. by a government organisation or university.  </p> </li> <li> <p>Unclear risk of bias: the trial did not declare its funding source.</p> </li> <li> <p>High risk of bias: the trial was industry funded, e.g. by a pharmaceutical company, or an author was an employee of a pharmaceutical company. </p> </li> </ul> </p> <p>We considered trials judged as being at low risk of bias in all of the specified individual domains as trials at low risk of bias. We considered trials judged as being at unclear risk of bias or high risk of bias in one or more of the specified individual domains as trials at high risk of bias. We contacted authors of the original reports to provide further details when any of the above information was unclear. </p> </section> </section> <section id="CD008716-sec-0040"> <h4 class="title">Measures of treatment effect</h4> <p>We conducted data analysis according to the guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008716-bbs2-0301" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>) and the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD008716-bbs2-0298" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 5. Art. No.: LIVER.">Gluud 2016</a>). </p> <p>For dichotomous data, we presented results as summary risk ratio (RR) with 95% confidence intervals (CI). For continuous data, we presented results as mean difference (MD) if outcomes were measured in the same way amongst trials. </p> </section> <section id="CD008716-sec-0041"> <h4 class="title">Unit of analysis issues</h4> <p>Trial participants as randomised per intervention group.</p> </section> <section id="CD008716-sec-0042"> <h4 class="title">Dealing with missing data</h4> <p>Data for all participants were analysed in the group to which they are allocated, regardless of whether or not they received the allocated intervention. If in the original reports participants were not analysed in the group to which they were randomised and there was sufficient information in the trial report, we attempted to restore these participants to the correct group, that is we conducted intention‐to‐treat analysis where it was possible to do so. Where data were missing, we sought clarification from the authors of the trial. If intention‐to‐treat analysis was not possible, we conducted available‐case analysis or per‐protocol analysis. </p> </section> <section id="CD008716-sec-0043"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity amongst trials, when appropriate, using the I² and Cochran Q statistics. Where we detected substantial heterogeneity (I² more than 50% or P less than 0.10), we explored this heterogeneity by prespecified subgroup analysis and sensitivity analysis. </p> </section> <section id="CD008716-sec-0044"> <h4 class="title">Assessment of reporting biases</h4> <p>Where we suspected reporting bias, we attempted to contact trial authors to provide the missing outcome data. When missing data were thought to potentially introduce serious bias, the impact of including such trials in the overall assessment of results was explored by a sensitivity analysis. Where there were at least 10 trials, we also used funnel plot asymmetry to assess the existence of bias. </p> </section> <section id="CD008716-sec-0045"> <h4 class="title">Data synthesis</h4> <p>We conducted statistical analysis with random‐effects model meta‐analyses using Review Manager 5 software (<a href="./references#CD008716-bbs2-0310" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2011</a>). We used random‐effects models for all analyses where trials examined the same intervention and the trials populations and methods were judged to be sufficiently similar. We originally planned to also conduct fixed‐effect model meta‐analysis, but abstained due to obvious heterogeneity of participants and intervention. We defined a P value of 0.05 or less as significant. </p> </section> <section id="CD008716-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The following were priori subgroup analyses.</p> <p> <ul id="CD008716-list-0013"> <li> <p>Type of probiotic (by genus): <i>Lactobacillus</i> , <i>Bifidobacteria</i>, mixed, or unclear. </p> </li> <li> <p>Grade of hepatic encephalopathy: minimal compared to overt.</p> </li> <li> <p>Duration of therapy.</p> </li> <li> <p>MELD (Model for End‐Stage Liver Disease) score.</p> </li> <li> <p>Co‐interventions used.</p> </li> <li> <p>Trials with low risk of bias compared to trials with high risk of bias.</p> </li> </ul> </p> <p>We assessed differences among subgroups by test of interaction (<a href="./references#CD008716-bbs2-0286" title="AltmanDG , BlandJM . Comparing several groups using analysis of variance. BMJ (Clinical Research Ed.)1996;312:1472-3.">Altman 1996</a>). </p> </section> <section id="CD008716-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analysis when we detected significant heterogeneity (I² more than 50% or P less than 0.10) to determine the source, that we sequentially removed trials from the analysis to determine which trial or trials were contributing to the heterogeneity. </p> <section id="CD008716-sec-0048"> <h5 class="title">'Summary of findings' tables</h5> <p>We used the GRADE system to evaluate the quality of the evidence for outcomes reported in the review, considering the within‐study risk of bias (methodological quality), inconsistency, imprecision, indirectness, and publication bias (<a href="./references#CD008716-bbs2-0299" title="Grade Working Group 2004-2007GRADEpro. BrozekJ , OxmanA , SchünemannH , Version 3.2 for Windows. Grade Working Group 2004-2007, 2008.">GRADEpro</a>). </p> <p>We defined the levels of evidence as 'high', 'moderate', 'low', or 'very low':</p> <p> <ul id="CD008716-list-0014"> <li> <p>High certainty: this research provides a very good indication of the likely effect; the likelihood that the effect will be substantially different is low. </p> </li> <li> <p>Moderate certainty: this research provides a good indication of the likely effect; the likelihood that the effect will be substantially different is moderate. </p> </li> <li> <p>Low certainty: this research provides some indication of the likely effect; however, the likelihood that the effect will be substantially different is high. </p> </li> <li> <p>Very low certainty: this research does not provide a reliable indication of the likely effect; the likelihood that the effect will be substantially different is very high. </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008716-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008716-sec-0049"></div> <section id="CD008716-sec-0050"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD008716-sec-0088" title="">Characteristics of included studies</a>; <a href="./references#CD008716-sec-0089" title="">Characteristics of excluded studies</a>; Characteristics of ongoing studies. </p> <section id="CD008716-sec-0051"> <h4 class="title">Results of the search</h4> <p>The process of identifying reports of randomised clinical trials for inclusion in the original review and in the review update is outlined in <a href="#CD008716-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD008716-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008716-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The original review published in 2011 included a total of seven trials reported in nine publications. </p> <p>In this update, the electronic searches of the Cochrane Hepato‐Biliary Group Controlled Trials Register (n = 13), the Cochrane Central Register of Controlled Trials (CENTRAL) (n = 58), MEDLINE (n = 85), Embase (n = 272), and Science Citation Index Expanded (n = 291) identified a total of 719 publications. We identified six additional trials from reference list (n = 4) and trials registry (n = 3) searching. </p> <p>After excluding 188 duplicates and 197 records overlapping with the original search, 341 unique records remained. Of these, we excluded 302 after reviewing titles and abstracts, and of the remaining 39 records, which we assessed after reviewing their full texts, we excluded a further 15 records. Three of the 39 records were identified as ongoing trials (<a href="./references#CD008716-bbs2-0278" title="ACTRN12610001021066. The effects of synbiotics, branched chain amino acids on hepatic encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12610001021066 (irst recieved 22 November 2010). ">ACTRN12610001021066</a>; <a href="./references#CD008716-bbs2-0279" title="IRCT201211012417N9. Effects of probiotics on the level of consciousness in patients with hepatic encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201211012417N9 (first received 24 November 2012). ">IRCT201211012417N9</a>; <a href="./references#CD008716-bbs2-0280" title="NCT01798329. Minimal hepatic encephalopathy in childhood and young adult: epidemiological study and pilot interventional study. clinicaltrials.gov/ct2/show/NCT01798329 (first recieved 19 February 2013). ">NCT01798329</a>); therefore, the results were not available for use in the review; information about these trials is provided in <a href="./references#CD008716-sec-0090" title="">Characteristics of studies awaiting classification</a>. </p> <p>Consequently, the review update contributed an additional 14 new trials reported in 20 publications. </p> <p>Seventeen reports were of 13 new trials (<a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a>; <a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a>; <a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a>; <a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a>; <a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a>; <a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a>; <a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a>; <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a>; <a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a>; <a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a>; <a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a>; <a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a>; <a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a>). Three reports were of one previously excluded trial now included after we obtained the manuscript from the author (<a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>). </p> <p>A total of 30 reports (publications and abstracts) of 21 trials qualified for inclusion in the review (<a href="#CD008716-fig-0001">Figure 1</a>). </p> <p>Four of these 21 trials were available as an abstract across four different reports (<a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a>; <a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a>; <a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a>; <a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a>), whilst 17 of these 21 trials were published in 26 different reports. </p> </section> <section id="CD008716-sec-0052"> <h4 class="title">Included studies</h4> <p>Of the 21 included trials, 14 trials compared a probiotic with placebo or no treatment in 785 participants (<a href="./references#CD008716-bbs2-0004" title="LiuQ , DuanZP , HaDK , BengmarkS , KurtovicJ , RiordanSM . Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.)2004;39(5):1441-9. ">Liu 2004</a>; <a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a>; <a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>; <a href="./references#CD008716-bbs2-0008" title="MalaguarneraM , GarganteMP , MalaguarneraG , SalmeriM , MastrojeniS , RampelloL , et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2010;22(2):199-206. ">Malaguarnera 2010</a>; <a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a>; <a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a>; <a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a>; <a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a>; <a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a>; <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a>; <a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a>; <a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a>; <a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a>; <a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a>). Three trials compared a probiotic with lactulose in 200 participants (<a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a>; <a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a>; <a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a>). Four trials compared a probiotic both with placebo and with lactulose in 435 participants (<a href="./references#CD008716-bbs2-0015" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. SharmaP , SharmaBC , PuriV , SarinSK . An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2008;20(6):506-11. SharmaP , SharmaBC , PuriV , SarinSK . A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. In: 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. Vol. 101. American College of Gastroenterology, 2006:402. ">Sharma 2008</a>; <a href="./references#CD008716-bbs2-0009" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. MittalVV , SharmaBC , SharmaP , SarinSK . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2011;23(8):725-32. [0954-691X]MittalVV , SharmaP , SharmaB , SarinSK . Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.)2009;4 (Suppl):471A. ">Mittal 2009</a>; <a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a>; <a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a>). </p> <p>The probiotics used in each trial are in <a href="#CD008716-tbl-0003">Table 1</a>. </p> <div class="table" id="CD008716-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of probiotics used across studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Probiotics used</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Streptococcus thermophilus</i> , <i>Lactobacillus bulgaricus</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus casei</i> , <i>Bifidobacteria</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus</i> GG AT strain 53103 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VSL#3 (containing <i>Bifidobacterium breve</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus bulgaricus</i> , <i>Streptococcus thermophilus</i>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0004" title="LiuQ , DuanZP , HaDK , BengmarkS , KurtovicJ , RiordanSM . Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.)2004;39(5):1441-9. ">Liu 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Pediacoccus pentosaceus</i> , <i>Leuconostoc mesenteroides</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus plantarum</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Enterococcus</i> lactic acid bacteria strain SF68 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Enterococcus faecium</i> strain SF68 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VSL#3 (containing <i>Streptococcus thermophilus</i> , <i>Bifidobacterium breve</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus bulgaricus</i>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0008" title="MalaguarneraM , GarganteMP , MalaguarneraG , SalmeriM , MastrojeniS , RampelloL , et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2010;22(2):199-206. ">Malaguarnera 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Bifidobacterium</i> (subtype not available) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0009" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. MittalVV , SharmaBC , SharmaP , SarinSK . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2011;23(8):725-32. [0954-691X]MittalVV , SharmaP , SharmaB , SarinSK . Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.)2009;4 (Suppl):471A. ">Mittal 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VSL#3 (containing <i>Streptococcus thermophilus</i> , <i>Bifidobacterium breve</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus bulgaricus</i>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VSL#3 (4 strains of <i>Lactobacillus</i> (<i>L acidophilus</i> DSM 24735, <i>L plantarum</i> DSM 24730, <i>L paracasei</i> DSM 24733, <i>L delbrueckii</i> subsp. <i>bulgaricus</i> DSM 24734), 3 strains of <i>Bifidobacterium</i> (<i>B longum</i> DSM 24736, <i>B breve</i> DSM 24732, <i>B infantis</i> DSM 24737), and 1 strain of <i>Streptococcus</i> (<i>S thermophilus</i> DSM 24731)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus acidophilus</i> , <i>Lactobacillus rhamnosus</i> , <i>Bifidobacterium longum</i> , <i>Saccharomyces boulardii</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium bifidum</i> , <i>Streptococcus thermophilus</i> (Bio Plus, Supherb, Israel) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bifid triple viable (not further specified)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus acidophilus</i> , <i>Lactobacillus rhamnosus</i> , <i>Bifidobacterium longum</i> , <i>Saccharomyces boulardii</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0015" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. SharmaP , SharmaBC , PuriV , SarinSK . An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2008;20(6):506-11. SharmaP , SharmaBC , PuriV , SarinSK . A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. In: 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. Vol. 101. American College of Gastroenterology, 2006:402. ">Sharma 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Enterococcus faecalis</i> , <i>Clostridium butyricum</i> , <i>Bacillus mesentricus</i> , lactic acid <i>Bacillus</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Velgut ERIS Pharmaceuticals, Ahmadabad, India (<i>Lactobacillus acidophilus</i> , <i>Lactobacillus rhamnosus</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus casei</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> , <i>Bifidobacterium breve</i> , <i>Saccharomyces boulardii</i> , <i>Streptococcus thermophilus</i>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Balance (Protexin Co., Somerset, UK) <i>Lactobacillus</i> strains (<i>L casei</i> , <i>L rhamnosus</i> , <i>L acidophilus</i> , <i>L bulgaricus</i> ), <i>Bifidobacterium</i> strains (<i>B breve</i> , <i>B longum)</i> , and <i>Streptococcus thermophilus</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus plantarum</i> 299v </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live <i>Bacillus cereus</i> capsules </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus acidophilus</i> </p> </td> </tr> </tbody> </table> </div> <p>Seventeen trials enrolled participants with minimal hepatic encephalopathy (<a href="./references#CD008716-bbs2-0004" title="LiuQ , DuanZP , HaDK , BengmarkS , KurtovicJ , RiordanSM . Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.)2004;39(5):1441-9. ">Liu 2004</a>; <a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a>; <a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>; <a href="./references#CD008716-bbs2-0015" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. SharmaP , SharmaBC , PuriV , SarinSK . An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2008;20(6):506-11. SharmaP , SharmaBC , PuriV , SarinSK . A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. In: 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. Vol. 101. American College of Gastroenterology, 2006:402. ">Sharma 2008</a>; <a href="./references#CD008716-bbs2-0009" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. MittalVV , SharmaBC , SharmaP , SarinSK . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2011;23(8):725-32. [0954-691X]MittalVV , SharmaP , SharmaB , SarinSK . Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.)2009;4 (Suppl):471A. ">Mittal 2009</a>; <a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a>; <a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a>; <a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a>; <a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a>; <a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a>; <a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a>; <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a>; <a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a>; <a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a>; <a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a>; <a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a>; <a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a>), and three trials enrolled participants with overt hepatic encephalopathy (grade I or II according to the West Haven criteria) (<a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a>; <a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a>; <a href="./references#CD008716-bbs2-0008" title="MalaguarneraM , GarganteMP , MalaguarneraG , SalmeriM , MastrojeniS , RampelloL , et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2010;22(2):199-206. ">Malaguarnera 2010</a>). The type of hepatic encephalopathy in one trial was unclear from the text (<a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a>). </p> </section> <section id="CD008716-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 320 newly identified and separate publications in the update. One previously excluded study was included after a manuscript containing further information was obtained from the author (<a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>). </p> </section> </section> <section id="CD008716-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>Reporting of trial methodology was incomplete for the majority of the domains, as summarised in <a href="#CD008716-fig-0002">Figure 2</a> and <a href="#CD008716-fig-0003">Figure 3</a>. We classified most trials at a high risk of bias (with the exception of <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a> and <a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>). </p> <div class="figure" id="CD008716-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD008716-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> </div> <div class="figure" id="CD008716-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD008716-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> </div> <section id="CD008716-sec-0055"> <h4 class="title">Allocation</h4> <p>Sequence generation was adequately performed in 12 trials (<a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a>; <a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a>; <a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>; <a href="./references#CD008716-bbs2-0015" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. SharmaP , SharmaBC , PuriV , SarinSK . An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2008;20(6):506-11. SharmaP , SharmaBC , PuriV , SarinSK . A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. In: 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. Vol. 101. American College of Gastroenterology, 2006:402. ">Sharma 2008</a>; <a href="./references#CD008716-bbs2-0009" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. MittalVV , SharmaBC , SharmaP , SarinSK . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2011;23(8):725-32. [0954-691X]MittalVV , SharmaP , SharmaB , SarinSK . Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.)2009;4 (Suppl):471A. ">Mittal 2009</a>; <a href="./references#CD008716-bbs2-0008" title="MalaguarneraM , GarganteMP , MalaguarneraG , SalmeriM , MastrojeniS , RampelloL , et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2010;22(2):199-206. ">Malaguarnera 2010</a>; <a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a>; <a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a>; <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a>; <a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a>; <a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a>; <a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a>), inadequately performed in one trial (<a href="./references#CD008716-bbs2-0004" title="LiuQ , DuanZP , HaDK , BengmarkS , KurtovicJ , RiordanSM . Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.)2004;39(5):1441-9. ">Liu 2004</a>), and unclear in eight trials (<a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a>; <a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a>; <a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a>; <a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a>; <a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a>; <a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a>; <a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a>; <a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a>). </p> <p>Seven trials reported adequate allocation concealment (<a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a>; <a href="./references#CD008716-bbs2-0004" title="LiuQ , DuanZP , HaDK , BengmarkS , KurtovicJ , RiordanSM . Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.)2004;39(5):1441-9. ">Liu 2004</a>; <a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>; <a href="./references#CD008716-bbs2-0009" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. MittalVV , SharmaBC , SharmaP , SarinSK . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2011;23(8):725-32. [0954-691X]MittalVV , SharmaP , SharmaB , SarinSK . Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.)2009;4 (Suppl):471A. ">Mittal 2009</a>; <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a>; <a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a>; <a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a>), two trials reported inadequate allocation concealment (<a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a>; <a href="./references#CD008716-bbs2-0015" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. SharmaP , SharmaBC , PuriV , SarinSK . An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2008;20(6):506-11. SharmaP , SharmaBC , PuriV , SarinSK . A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. In: 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. Vol. 101. American College of Gastroenterology, 2006:402. ">Sharma 2008</a>), and 12 trials were unclear about their method of allocation concealment (<a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a>; <a href="./references#CD008716-bbs2-0008" title="MalaguarneraM , GarganteMP , MalaguarneraG , SalmeriM , MastrojeniS , RampelloL , et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2010;22(2):199-206. ">Malaguarnera 2010</a>; <a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a>; <a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a>; <a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a>; <a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a>; <a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a>; <a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a>; <a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a>; <a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a>; <a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a>; <a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a>). </p> </section> <section id="CD008716-sec-0056"> <h4 class="title">Blinding</h4> <p>Three trials reported adequate blinding of participants, outcome assessors, and personnel (<a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a>; <a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>; <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a>). One trial reported adequate blinding of outcome assessors and participants, but was unclear regarding blinding of personnel (<a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a>). Three trials reported adequate blinding of outcome assessors, but reported no blinding of participants and personnel (<a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a>; <a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a>; <a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a>). One trial was unclear regarding blinding of outcome assessors, but reported no blinding of participants and personnel (<a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a>). One trial reported blinding of participants, but was unclear regarding blinding of personnel and outcome assessors (<a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a>). Three trials did not blind participants, personnel, or outcome assessors (<a href="./references#CD008716-bbs2-0015" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. SharmaP , SharmaBC , PuriV , SarinSK . An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2008;20(6):506-11. SharmaP , SharmaBC , PuriV , SarinSK . A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. In: 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. Vol. 101. American College of Gastroenterology, 2006:402. ">Sharma 2008</a>; <a href="./references#CD008716-bbs2-0009" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. MittalVV , SharmaBC , SharmaP , SarinSK . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2011;23(8):725-32. [0954-691X]MittalVV , SharmaP , SharmaB , SarinSK . Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.)2009;4 (Suppl):471A. ">Mittal 2009</a>; <a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a>). The remaining nine trials were unclear regarding the conduct of blinding (<a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a>; <a href="./references#CD008716-bbs2-0004" title="LiuQ , DuanZP , HaDK , BengmarkS , KurtovicJ , RiordanSM . Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.)2004;39(5):1441-9. ">Liu 2004</a>; <a href="./references#CD008716-bbs2-0008" title="MalaguarneraM , GarganteMP , MalaguarneraG , SalmeriM , MastrojeniS , RampelloL , et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2010;22(2):199-206. ">Malaguarnera 2010</a>; <a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a>; <a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a>; <a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a>; <a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a>; <a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a>; <a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a>). </p> </section> <section id="CD008716-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete outcome data were adequately addressed in six trials (<a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a>; <a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>; <a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a>; <a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a>; <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a>; <a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a>), inadequately addressed in four trials (<a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a>; <a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a>; <a href="./references#CD008716-bbs2-0015" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. SharmaP , SharmaBC , PuriV , SarinSK . An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2008;20(6):506-11. SharmaP , SharmaBC , PuriV , SarinSK . A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. In: 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. Vol. 101. American College of Gastroenterology, 2006:402. ">Sharma 2008</a>; <a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a>), and unclear in the remaining trials (<a href="./references#CD008716-bbs2-0004" title="LiuQ , DuanZP , HaDK , BengmarkS , KurtovicJ , RiordanSM . Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.)2004;39(5):1441-9. ">Liu 2004</a>; <a href="./references#CD008716-bbs2-0009" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. MittalVV , SharmaBC , SharmaP , SarinSK . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2011;23(8):725-32. [0954-691X]MittalVV , SharmaP , SharmaB , SarinSK . Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.)2009;4 (Suppl):471A. ">Mittal 2009</a>; <a href="./references#CD008716-bbs2-0008" title="MalaguarneraM , GarganteMP , MalaguarneraG , SalmeriM , MastrojeniS , RampelloL , et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2010;22(2):199-206. ">Malaguarnera 2010</a>; <a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a>; <a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a>; <a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a>; <a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a>; <a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a>; <a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a>; <a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a>; <a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a>). </p> </section> <section id="CD008716-sec-0058"> <h4 class="title">Selective reporting</h4> <p>Four trials were free of selective outcome reporting (<a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a>; <a href="./references#CD008716-bbs2-0015" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. SharmaP , SharmaBC , PuriV , SarinSK . An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2008;20(6):506-11. SharmaP , SharmaBC , PuriV , SarinSK . A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. In: 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. Vol. 101. American College of Gastroenterology, 2006:402. ">Sharma 2008</a>; <a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a>; <a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a>), while the remaining 17 trials were unclear (<a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a>; <a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a>; <a href="./references#CD008716-bbs2-0004" title="LiuQ , DuanZP , HaDK , BengmarkS , KurtovicJ , RiordanSM . Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.)2004;39(5):1441-9. ">Liu 2004</a>; <a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>; <a href="./references#CD008716-bbs2-0009" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. MittalVV , SharmaBC , SharmaP , SarinSK . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2011;23(8):725-32. [0954-691X]MittalVV , SharmaP , SharmaB , SarinSK . Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.)2009;4 (Suppl):471A. ">Mittal 2009</a>; <a href="./references#CD008716-bbs2-0008" title="MalaguarneraM , GarganteMP , MalaguarneraG , SalmeriM , MastrojeniS , RampelloL , et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2010;22(2):199-206. ">Malaguarnera 2010</a>; <a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a>; <a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a>; <a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a>; <a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a>; <a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a>; <a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a>; <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a>; <a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a>; <a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a>; <a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a>; <a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a>). </p> </section> <section id="CD008716-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>Eight trials declared their funding source (<a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a>; <a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a>; <a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>; <a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a>; <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a>; <a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a>; <a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a>; <a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a>), of which six were independently funded (<a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a>; <a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a>; <a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a>; <a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a>; <a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a>; <a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a>), and two were industry funded (<a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a>; <a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a>). The remaining trials did not disclose their funding source (<a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a>; <a href="./references#CD008716-bbs2-0004" title="LiuQ , DuanZP , HaDK , BengmarkS , KurtovicJ , RiordanSM . Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.)2004;39(5):1441-9. ">Liu 2004</a>; <a href="./references#CD008716-bbs2-0015" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. SharmaP , SharmaBC , PuriV , SarinSK . An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2008;20(6):506-11. SharmaP , SharmaBC , PuriV , SarinSK . A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. In: 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. Vol. 101. American College of Gastroenterology, 2006:402. ">Sharma 2008</a>; <a href="./references#CD008716-bbs2-0009" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. MittalVV , SharmaBC , SharmaP , SarinSK . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2011;23(8):725-32. [0954-691X]MittalVV , SharmaP , SharmaB , SarinSK . Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.)2009;4 (Suppl):471A. ">Mittal 2009</a>; <a href="./references#CD008716-bbs2-0008" title="MalaguarneraM , GarganteMP , MalaguarneraG , SalmeriM , MastrojeniS , RampelloL , et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2010;22(2):199-206. ">Malaguarnera 2010</a>; <a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a>; <a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a>; <a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a>; <a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a>; <a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a>; <a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a>; <a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a>; <a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a>). </p> </section> </section> <section id="CD008716-sec-0060"> <h3 class="title" id="CD008716-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD008716-tbl-0001"><b>Summary of findings 1</b> Probiotic for people with hepatic encephalopathy</a>; <a href="./full#CD008716-tbl-0002"><b>Summary of findings 2</b> Probiotics for people with hepatic encephalopathy</a> </p> <p><b>Probiotic versus placebo or no treatment</b> </p> <p><i><b>Primary outcomes</b> </i> </p> <p><b>All‐cause mortality</b> </p> <p>There were no significant differences in all‐cause mortality (<a href="./references#CD008716-fig-0004" title="">Analysis 1.1</a>; 7 trials; 404 participants; RR 0.58, 95% CI 0.23 to 1.44; low quality of evidence). </p> <p>Number of participants who did not recover from hepatic encephalopathy</p> <p>No‐recovery (as measured by incomplete resolution of symptoms) was significantly lower for participants treated with probiotic than with placebo or no intervention overall (<a href="./references#CD008716-fig-0005" title="">Analysis 1.2</a>; 10 trials; 574 participants; RR 0.67, 95% CI 0.56 to 0.79; moderate quality of evidence), at one month (<a href="./references#CD008716-fig-0005" title="">Analysis 1.2</a> (Analysis 1.2.1); 4 trials; 228 participants; RR 0.75, 95% CI 0.58 to 0.96), and at three months (<a href="./references#CD008716-fig-0005" title="">Analysis 1.2</a> (Analysis 1.2.3); 3 trials; 229 participants; RR 0.58, 95% CI 0.43 to 0.78), but not at two months (<a href="./references#CD008716-fig-0005" title="">Analysis 1.2</a> (Analysis 1.2.2); 3 trials; 117 participants; RR 0.65, 95% CI 0.38 to 1.10). </p> <p><b>Adverse events</b> </p> <p>Adverse events were lower for participants treated with probiotic than with placebo or no intervention when considering the development of overt hepatic encephalopathy (<a href="./references#CD008716-fig-0006" title="">Analysis 1.3</a> (Analysis 1.3.1); 10 trials; 585 participants; RR 0.29, 95% CI 0.16 to 0.51; low quality of evidence), but there were no significant differences for hospitalisation (<a href="./references#CD008716-fig-0006" title="">Analysis 1.3</a> (Analysis 1.3.3); 3 trials; 163 participants; RR 0.67, 95% CI 0.11 to 4.00; very low quality of evidence) or change of/or withdrawal from treatment (<a href="./references#CD008716-fig-0006" title="">Analysis 1.3</a> (Analysis 1.3.5); 9 trials; 551 participants; RR 0.70, 95% CI 0.46 to 1.07; very low quality of evidence). </p> <p><b>Quality of life</b> </p> <p>There were no significant differences in quality of life scores for participants treated with probiotic than with no intervention in the SF‐36 Physical Functioning Scale (<a href="./references#CD008716-fig-0007" title="">Analysis 1.4</a> (Analysis 1.4.1); 1 trial; 20 participants; MD 0.00, 95% CI ‐5.47 to 5.47; low quality of evidence) and the SF‐36 Mental Health Scale (<a href="./references#CD008716-fig-0007" title="">Analysis 1.4</a> (Analysis 1.4.2); 1 trial; 20 participants; MD ‐4.00, 95% CI ‐9.82 to 1.82; low quality of evidence). There was no significant difference in quality of life score for participants treated with probiotic than with no intervention in the Total Sickness Impact Profile (SIP) Score (<a href="./references#CD008716-fig-0007" title="">Analysis 1.4</a> (Analysis 1.4.3); 2 trials; 95 participants; MD ‐3.66, 95% CI ‐7.75 to 0.44; low quality of evidence), but there were significant differences for change in SIP Psychological Score (<a href="./references#CD008716-fig-0007" title="">Analysis 1.4</a> (Analysis 1.4.4); 2 trials; 95 participants; MD ‐3.54, 95% CI ‐4.95 to ‐2.12; low quality of evidence) and change in SIP Physical Score (<a href="./references#CD008716-fig-0007" title="">Analysis 1.4</a> (Analysis 1.4.5); 2 trials; 95 participants; MD ‐2.94, 95% CI ‐4.44 to ‐1.44; low quality of evidence). A reduced SIP score indicates improved quality of life. </p> <p><i><b>Secondary outcomes</b> </i> </p> <p><b>Sepsis</b> </p> <p>There were no reports of septicaemia attributable to probiotic in any trial.</p> <p><b>Change in plasma ammonia concentration</b> </p> <p>Plasma ammonia concentration was significantly lower for participants treated with probiotic than with no intervention overall (<a href="./references#CD008716-fig-0008" title="">Analysis 1.5</a>; 10 trials; 705 participants; MD ‐8.29 μmol/L, 95% CI ‐13.17 to ‐3.41; low quality of evidence), at one month (<a href="./references#CD008716-fig-0008" title="">Analysis 1.5</a> (Analysis 1.5.1); 5 trials; 357 participants; MD ‐5.55 μmol/L, 95% CI ‐10.67 to ‐0.42), at three months (<a href="./references#CD008716-fig-0008" title="">Analysis 1.5</a> (Analysis 1.5.3); 1 trial; 73 participants; MD ‐6.79 μmol/L, 95% CI ‐10.39 to ‐3.19), and at six months (<a href="./references#CD008716-fig-0008" title="">Analysis 1.5</a> (Analysis 1.5.3); 1 trial; 64 participants; MD ‐31.08 μmol/L, 95% CI ‐40.50 to ‐21.66), but not at two months (<a href="./references#CD008716-fig-0008" title="">Analysis 1.5</a> (Analysis 1.5.2); 4 trials; 211 participants; MD ‐5.11 μmol/L, 95% CI ‐14.56 to 4.34). </p> <p><b>Duration of hospital stay: measured in days</b> </p> <p>No trials reported duration of hospital stay.</p> <p><b>Subgroup analysis</b> </p> <p>We performed subgroup analyses for the outcomes no‐recovery (<a href="./references#CD008716-fig-0005" title="">Analysis 1.2</a>) and plasma ammonia concentration (<a href="./references#CD008716-fig-0008" title="">Analysis 1.5</a>) using the prespecified subgroups (<a href="#CD008716-sec-0046">Subgroup analysis and investigation of heterogeneity</a>). We could not perform subgroup analyses by MELD score, as most trials did not report this, or by risk of bias, as we judged most trials at high risk of bias. </p> <p><b>No‐recovery</b> </p> <p>We detected no significant differences for the following subgroup analyses: type of probiotic used, test for subgroup differences: Chi² = 0.74, df = 2 (P = 0.69); grade of hepatic encephalopathy, test for subgroup differences: Chi² = 3.56, df = 1 (P = 0.06); duration of therapy, test for subgroup differences: Chi² = 1.68, df = 2 (P = 0.43); co‐interventions used, test for subgroup differences: Chi² = 3.57, df = 2 (P = 0.17) (<a href="#CD008716-tbl-0004">Table 2</a>). </p> <div class="table" id="CD008716-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heterogeneity subgroup analysis</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Probiotic versus placebo or no intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No‐recovery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect estimate</b> </p> <p><b>Risk ratio [95% CI]</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference P</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Type of probiotic</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactobacillus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 [0.45, 1.00]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 [0.50, 0.83]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76 [0.58, 0.98]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Grade of hepatic encephalopathy</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 [0.52, 0.76]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 [0.64, 1.48]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Duration of therapy</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt;= 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 [0.58, 0.96]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 &gt; 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 [0.38, 1.10]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 + months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 [0.43, 0.78]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Co‐interventions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 [0.52, 0.76]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bioactive fermentable fibre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 [0.54, 1.86]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactulose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 [0.55, 1.69]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Plasma ammonia concentration</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect estimate</b> </p> <p><b>Mean difference [95% CI]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference P</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Type of probiotic</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bifidobacterium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.35 [‐16.09, ‐2.61]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactobacillus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.90 [‐24.41, 0.60]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.80 [‐9.65, 6.06]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐17.02 [‐44.07, 10.02]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Grade of hepatic encephalopathy</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.50 [‐14.38, ‐2.62]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.35 [‐16.09, ‐2.61]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Duration of therapy</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt;=1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.93 [‐12.25, 0.39]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 &gt; 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.11 [‐14.56, 4.34]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 + months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐18.53 [‐42.32, 5.26]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Co‐interventions used</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10.42 [‐18.68, ‐2.17]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bioactive fermentable fibre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.90 [‐5.51, ‐0.29]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactulose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7.88 [‐14.29, ‐1.47]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Probiotic versus lactulose</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Plasma ammonia concentration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect estimate</b> </p> <p><b>Mean difference [95% CI]</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference P</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Type of probiotic</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enterococcus SF68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.83 [‐24.51, ‐1.15]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34 [‐1.72, 4.40]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactobacillus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.17 [‐17.17, 10.83]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.31 [‐5.70, 8.32]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Grade of hepatic encephalopathy</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.16 [‐1.59, 3.91]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overt</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.83 [‐24.51, ‐1.15]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval</p> </div> </div> <p><b>Plasma ammonia</b> </p> <p>We detected no significant differences for the following subgroup analyses: type of probiotic used, test for subgroup differences: Chi² = 3.26, df = 3 (P = 0.35); grade of hepatic encephalopathy, test for subgroup differences: Chi² = 0.03, df = 1 (P = 0.85); duration of therapy, test for subgroup differences: Chi² = 1.09, df = 2 (P = 0.58); co‐interventions used, test for subgroup differences: Chi² = 4.40, df = 2 (P = 0.11) (<a href="#CD008716-tbl-0004">Table 2</a>). </p> <p><b>Quality of the evidence</b> </p> <p>In the analyses comparing probiotic versus placebo or no intervention (<a href="./full#CD008716-tbl-0001">summary of findings Table 1</a>), we downgraded the quality of the evidence to 'moderate' for the outcome no‐recovery because the included trials were at high risk of bias. Likewise, we downgraded the quality of the evidence for the outcomes adverse events ‐‐ overt hepatic encephalopathy and plasma ammonia concentration to low because the included trials were at high risk of bias and the results were inconsistent. We downgraded the quality of the evidence for the outcomes all‐cause mortality and adverse events ‐‐ change of or withdrawal from treatment or both ‐‐ to very low because the included trials were at high risk of bias and the results were inconsistent or imprecise, or both. </p> <p><b>Heterogeneity</b> </p> <p>Heterogeneity was demonstrated for the outcome no‐recovery (<a href="./references#CD008716-fig-0005" title="">Analysis 1.2</a>) (Chi² = 17.48, df = 9 (P = 0.04); I² = 48%) and did not seem attributable to type of probiotic used, grade of hepatic encephalopathy, duration of therapy, or co‐interventions used. Heterogeneity was demonstrated for the outcome plasma ammonia concentration (<a href="./references#CD008716-fig-0008" title="">Analysis 1.5</a>) (Chi² = 47.32, df = 9 (P &lt; 0.00001); I² = 81%) and did not seem attributable to type of probiotic used, grade of hepatic encephalopathy, duration of therapy, or co‐interventions used (<a href="#CD008716-tbl-0004">Table 2</a>). </p> <p><b>Probiotic versus lactulose</b> </p> <p><i><b>Primary outcomes</b> </i> </p> <p><b>All‐cause mortality</b> </p> <p>There were no significant differences in all‐cause mortality (<a href="./references#CD008716-fig-0009" title="">Analysis 2.1</a>; 2 trials; 200 participants; RR 5.00, 95% CI 0.25 to 102.00; very low quality of evidence). </p> <p>Number of participants who did not recover from hepatic encephalopathy</p> <p>There was no significant difference in lack of recovery (<a href="./references#CD008716-fig-0010" title="">Analysis 2.2</a>; 7 trials; 430 participants; RR 1.01, 95% CI 0.85 to 1.21; very low quality of evidence). </p> <p><b>Adverse events</b> </p> <p>There was no significant difference between participants treated with probiotic and those treated with lactulose for adverse events when considering the development of overt hepatic encephalopathy (<a href="./references#CD008716-fig-0011" title="">Analysis 2.3</a> (Analysis 2.3.1); 6 trials; 420 participants; RR 1.17, 95% CI 0.63 to 2.17; very low quality of evidence), hospitalisation (<a href="./references#CD008716-fig-0011" title="">Analysis 2.3</a> (Analysis 2.3.3); 1 trial; 80 participants; RR 0.33, 95% CI 0.04 to 3.07; very low quality of evidence), intolerance leading to discontinuation (<a href="./references#CD008716-fig-0011" title="">Analysis 2.3</a> (Analysis 2.3.4); 3 trials; 220 participants; RR 0.35, 95% CI 0.08 to 1.43; very low quality of evidence), or change of/or withdrawal from treatment (<a href="./references#CD008716-fig-0011" title="">Analysis 2.3</a> (Analysis 2.3.5); 7 trials; 490 participants; RR 1.27, 95% CI 0.88 to 1.82; very low quality of evidence). </p> <p><b>Quality of life</b> </p> <p>There were no significant differences in quality of life scores between participants treated with probiotic and those treated with lactulose in change in Total SIP Score (<a href="./references#CD008716-fig-0012" title="">Analysis 2.4</a> (Analysis 2.4.1); 1 trial; 69 participants; MD 0.65, 95% CI ‐1.13 to 2.43; very low quality of evidence); change in SIP Psychological Score (<a href="./references#CD008716-fig-0012" title="">Analysis 2.4</a> (Analysis 2.4.2); 1 trial; 69 participants; MD 0.48, 95% CI ‐1.04 to 2.00; very low quality of evidence), or change in SIP Physical Score (<a href="./references#CD008716-fig-0012" title="">Analysis 2.4</a> (Analysis 2.4.3); 1 trial; 69 participants; MD 0.38, 95% CI ‐0.61 to 1.37; very low quality of evidence). </p> <p><i><b>Secondary outcomes</b> </i> </p> <p><b>Sepsis</b> </p> <p>There were no reports of septicaemia attributable to probiotic in any trial.</p> <p><b>Change in plasma ammonia concentration</b> </p> <p>There was no significant difference in plasma ammonia concentration overall (<a href="./references#CD008716-fig-0013" title="">Analysis 2.5</a>; 6 trials; 325 participants; MD ‐2.93 μmol/L, 95% CI ‐9.36 to 3.50; very low quality of evidence), at one month or less (<a href="./references#CD008716-fig-0013" title="">Analysis 2.5</a> (Analysis 2.5.1); 5 trials; 248 participants; MD ‐4.30 μmol/L, 95% CI ‐13.17 to 4.56), or at three months (<a href="./references#CD008716-fig-0013" title="">Analysis 2.5</a> (Analysis 2.5.2); 1 trial; 77 participants; MD 1.16 μmol/L, 95% CI ‐1.96 to 4.28). </p> <p><b>Duration of hospital stay: measured in days</b> </p> <p>No trial reported duration of hospital stay.</p> <p><b>Subgroup analysis</b> </p> <p>We performed subgroup analyses for the outcome plasma ammonia concentration (<a href="./references#CD008716-fig-0013" title="">Analysis 2.5</a>) using the prespecified subgroups (<a href="#CD008716-sec-0046">Subgroup analysis and investigation of heterogeneity</a>).<br/>We did not perform subgroup analyses by MELD score as this was not reported in most trials, nor by risk of bias as the majority of the trials were at high risk of bias. </p> <p><b>Plasma ammonia</b> </p> <p>We detected a significant difference for the subgroup analyses on grade of hepatic encephalopathy, test for subgroup differences: Chi² = 5.22, df = 1 (P = 0.02); I² = 80.9%. We detected no significant difference for the subgroup analyses on type of probiotic used, test for subgroup differences: Chi² = 5.60, df = 3 (P = 0.13) (<a href="#CD008716-tbl-0004">Table 2</a>). </p> <p><b>Quality of the evidence</b> </p> <p>In the analyses comparing probiotic versus lactulose (<a href="./full#CD008716-tbl-0002">summary of findings Table 2</a>), we downgraded the quality of the evidence to very low for all outcomes due to concerns that the included trials were at high risk of bias, the results were inconsistent or imprecise or both, and because a surrogate marker was used for clinically important outcomes. </p> <p><b>Heterogeneity</b> </p> <p>Heterogeneity was demonstrated for the outcome plasma ammonia concentration (<a href="./references#CD008716-fig-0013" title="">Analysis 2.5</a>) (Chi² = 11.87, df = 4 (P = 0.02); I² = 66%). Heterogeneity seemed largely attributable to the grade of hepatic encephalopathy, and it did not seem attributable to the type of probiotic used (<a href="#CD008716-tbl-0004">Table 2</a>). </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008716-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008716-sec-0061"></div> <section id="CD008716-sec-0062"> <h3 class="title" id="CD008716-sec-0062">Summary of main results</h3> <p>We included 21 trials with a total of 1420 randomised participants. The trials used a variety of probiotics, although the most commonly used probiotic was VSL#3, a proprietary name for a group of eight probiotics. Duration of administration of the experimental intervention varied from 10 days to 180 days. We classified 19 of 21 trials as having a high risk of bias. </p> <p>Probiotics may lead to little or no difference in mortality from any cause compared with no treatment. Probiotics probably improve recovery from hepatic encephalopathy (as measured by resolution of symptoms) compared with no treatment. Probiotics may prevent the development of overt hepatic encephalopathy compared with no treatment. The effects of probiotics on change of/or withdrawal from treatment is uncertain because the quality of the evidence was very low. Quality of life may slightly improve for patients treated with probiotic than with no intervention. Plasma ammonia concentration may decrease for patients treated with probiotic than with no intervention. No trial reported duration of hospital stay. </p> <p>It is uncertain whether probiotics are better than lactulose for the management of hepatic encephalopathy, because the available evidence was of very low quality across all outcomes. There were no reports of septicaemia attributable to probiotic in any trial. </p> </section> <section id="CD008716-sec-0063"> <h3 class="title" id="CD008716-sec-0063">Overall completeness and applicability of evidence</h3> <p>The number of trials and randomised participants included in this review has substantially increased with this update. However, data from some trials were only available in abstract form; outcomes were often inconsistently reported; and most trials were at high risk of bias and included few participants. There is thus limited evidence for the use of probiotics as a treatment for people with hepatic encephalopathy. Overall, there is a large number of trials on probiotic use in cirrhosis (without confirmed diagnosis of hepatic encephalopathy). We have not considered trials of primary or secondary prevention using probiotics as prophylaxis against hepatic encephalopathy in the present review, which ought to be the subject of another systematic review. Also, trials on synbiotics should be considered for inclusion in the future alongside probiotics as a separate subgroup to illustrate comparative efficacy. </p> </section> <section id="CD008716-sec-0064"> <h3 class="title" id="CD008716-sec-0064">Quality of the evidence</h3> <p>Although compared to the original 2011 review the quantity of evidence has increased, the quality of evidence has lagged behind and is far from optimal. Although there may be emerging evidence for probiotic use, the quality of evidence for their use is low. Further randomised clinical trials with improved methodological quality and outcome data collection and data reporting are required to fully establish the role of probiotics in hepatic encephalopathy. The use of tools that quantify the statistical reliability of data across cumulative meta‐analysis such as Trial Sequential Analysis, <a href="./references#CD008716-bbs2-0324" title="Copenhagen Trial UnitTSA - Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011. www.ctu.dk/tsa/downloads.aspx.">TSA 2011</a>, ought to be included in future updates (<a href="./references#CD008716-bbs2-0328" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [0895-4356]">Wetterslev 2008</a>; <a href="./references#CD008716-bbs2-0323" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 13 June 2016).">Thorlund 2011</a>). We also need to search data‐bases of regulatory authorities for additional trials. </p> </section> <section id="CD008716-sec-0065"> <h3 class="title" id="CD008716-sec-0065">Potential biases in the review process</h3> <p>This systematic review with meta‐analysis was undertaken with broad inclusion criteria to assess the totality of available evidence. Our literature search was comprehensive and did not exclude trials based on language of publication or publication status. We attempted to contact authors wherever trial data and methodology were unclear. All data extraction and analysis was undertaken by several authors working independently to minimise bias. Despite these strengths, there were some limitations: for example, we were not blinded to authorship during data extraction and 'Risk of bias' assessment. While we did attempt to contact study authors, we were not always certain that our messages were received, and we did not attempt to make any further contact if we received no response to our initial emails. As stated above, we might have missed trials by not searching databases of regulatory authorities, and we did not control risks of random errors. </p> </section> <section id="CD008716-sec-0066"> <h3 class="title" id="CD008716-sec-0066">Agreements and disagreements with other studies or reviews</h3> <p>A review published in 2011 discusses the effects of prebiotics, probiotics, and synbiotics in minimal hepatic encephalopathy (<a href="./references#CD008716-bbs2-0320" title="ShuklaS , ShuklaA , MehboobS , GuhaS . Meta analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Alimentary Pharmacology &amp; Therapeutics2011;33:662-71.">Shukla 2011a</a>). As our review did not evaluate the combination of probiotics, prebiotics, and synbiotics, it is not possible to make direct comparisons between the reviews. Of note, the <a href="./references#CD008716-bbs2-0320" title="ShuklaS , ShuklaA , MehboobS , GuhaS . Meta analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Alimentary Pharmacology &amp; Therapeutics2011;33:662-71.">Shukla 2011a</a> review was only able to locate two trials of probiotics including participants with minimal hepatic encephalopathy, compared to the five trials in the previous version of our review (<a href="./references#CD008716-bbs2-0331" title="McGeeRG , BakensA , WileyK , RiordanSM , WebsterAC . Probiotics for patients with hepatic encephalopathy. Cochrane Database of Systematic Reviews2011, Issue 11. Art. No: CD008716. [DOI: 10.1002/14651858.CD008716.pub2] [1361-6137]">McGee 2011</a>), suggesting that we utilised a more sensitive search strategy. </p> <p>A 2011 meta‐analysis found improvement in “clinical and biochemical parameters in patients with minimal hepatic encephalopathy” and a “decrease the morbidity of clinical hepatic encephalopathy” (<a href="./references#CD008716-bbs2-0243" title="TangSH , WangKJ , WuXJ , ZhangMM . Efficacy of probiotics in the treatment of minimal hepatic encephalopathy: a meta analysis. World Chinese Journal of Digestology2011;19:2587-92. ">Tang 2011</a>). However, that study used the time of Number Connection Test as a surrogate for clinical resolution of symptoms. In addition, they used a fixed‐effect model, while we used the random‐effects model in our review. </p> <p>A 2012 review published a study, <a href="./references#CD008716-bbs2-0110" title="HolteK , KragA , GluudLL . Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatology Research2012;42:1008-15. ">Holte 2012</a>, with results largely similar to the initial 2011 publication of our systematic review and meta‐analysis (<a href="./references#CD008716-bbs2-0331" title="McGeeRG , BakensA , WileyK , RiordanSM , WebsterAC . Probiotics for patients with hepatic encephalopathy. Cochrane Database of Systematic Reviews2011, Issue 11. Art. No: CD008716. [DOI: 10.1002/14651858.CD008716.pub2] [1361-6137]">McGee 2011</a>). </p> <p>A meta‐analysis published in 2015 included nine randomised clinical trials comparing probiotic against placebo or no treatment (<a href="./references#CD008716-bbs2-0330" title="ZhaoLN , YuT , LanSY , HouJT , ZhangZZ , WangSS , et al. Probiotics can improve the clinical outcomes of hepatic encephalopathy: An update meta-analysis. Clinics and Research in Hepatology and Gastroenterology2015;39(6):674-82. [2210-7401]">Zhao 2015</a>). The authors concluded that probiotics were “associated with improvement of minimal hepatic encephalopathy, prophylaxis of overt hepatic encephalopathy, and reduction of SIP score and severe adverse events”, and our findings mirror these findings to some extent. They grouped serious adverse events as any of “minimal hepatic encephalopathy developing into overt hepatic encephalopathy, hospitalisations, infections, or unrelated emergency room (ER) visits”. However, we have separated these adverse events into subgroups, and found a significant difference favouring probiotics only for reducing the progression to overt hepatic encephalopathy, and not for the other serious adverse events. Furthermore, we have graded our findings to reflect the quality of the available evidence and the subsequent uncertainty around the results. In addition, due to the small sample sizes involved, random error or chance findings may partly explain the observed differences. Our review did not address the issue of prophylaxis of hepatic encephalopathy. </p> <p>Another 2015 meta‐analysis of probiotic use in hepatic encephalopathy included observational data as well as randomised clinical trials, but found only 14 studies, where we have included 21 randomised clinical trials (<a href="./references#CD008716-bbs2-0314" title="SaabS , SuraweeraD , AuJ , SaabEG , AlperTS , TongMJ . Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver International 2015 Nov 12 [Epub ahead of print]. [1478-3231]">Saab 2015</a>). Saab and colleagues found that when probiotics were compared with placebo, there was a significant improvement in minimal hepatic encephalopathy and decreased progression to overt hepatic encephalopathy, which is consistent with our findings. This study also reported no significant difference in improvement of minimal hepatic encephalopathy, hospitalisation rates, or progression to overt hepatic encephalopathy when probiotics were compared with lactulose, which is again consistent with our findings. However, the Saab study noted significantly decreased hospitalisation rates when probiotics were compared with placebo, which we did not. This is likely due to bias from their observational data and incomplete evidence synthesis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008716-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008716-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD008716-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD008716-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotic versus placebo or no intervention, Outcome 1: All‐cause mortality" data-id="CD008716-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Probiotic versus placebo or no intervention, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotic versus placebo or no intervention, Outcome 2: No recovery (incomplete resolution of clinical symptoms)" data-id="CD008716-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Probiotic versus placebo or no intervention, Outcome 2: No recovery (incomplete resolution of clinical symptoms) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotic versus placebo or no intervention, Outcome 3: Adverse events" data-id="CD008716-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Probiotic versus placebo or no intervention, Outcome 3: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotic versus placebo or no intervention, Outcome 4: Quality of life" data-id="CD008716-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Probiotic versus placebo or no intervention, Outcome 4: Quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotic versus placebo or no intervention, Outcome 5: Plasma ammonia concentration (final and change scores) (μmol/L)" data-id="CD008716-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Probiotic versus placebo or no intervention, Outcome 5: Plasma ammonia concentration (final and change scores) (μmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotic versus lactulose, Outcome 1: All‐cause mortality" data-id="CD008716-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Probiotic versus lactulose, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotic versus lactulose, Outcome 2: No recovery (incomplete resolution of clinical symptoms)" data-id="CD008716-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Probiotic versus lactulose, Outcome 2: No recovery (incomplete resolution of clinical symptoms) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotic versus lactulose, Outcome 3: Adverse events" data-id="CD008716-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Probiotic versus lactulose, Outcome 3: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotic versus lactulose, Outcome 4: Health‐related quality of life" data-id="CD008716-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Probiotic versus lactulose, Outcome 4: Health‐related quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008716-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/urn:x-wiley:14651858:media:CD008716:CD008716-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotic versus lactulose, Outcome 5: Plasma ammonia concentration (final and change scores) (μmol/L)" data-id="CD008716-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_t/tCD008716-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Probiotic versus lactulose, Outcome 5: Plasma ammonia concentration (final and change scores) (μmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/media/CDSR/CD008716/image_n/nCD008716-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008716-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Probiotic for people with hepatic encephalopathy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotic versus placebo or no intervention for people with hepatic encephalopathy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with hepatic encephalopathy<br/><b>Setting:</b> inpatients<br/><b>Intervention:</b> probiotic<br/><b>Comparison:</b> placebo/no intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with probiotic</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>All‐cause mortality</p> <p>(follow‐up: 2 weeks to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.58<br/>(0.23 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>404<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/>(12 to 73) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(6 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No‐recovery (incomplete resolution of clinical symptoms)</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.67<br/>(0.56 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>574<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>790 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>529 per 1000<br/>(442 to 624) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>877 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>588 per 1000<br/>(491 to 693) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events ‐ Overt hepatic encephalopathy</p> <p>(follow‐up: 2 weeks to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.29<br/>(0.16 to 0.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>585<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/>(27 to 86) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/>(27 to 86) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events ‐ Change of/or withdrawal from treatment</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.70<br/>(0.46 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>551<br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>204 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000<br/>(94 to 219) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/>(73 to 169) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma ammonia concentration (final and change scores) (μmol/L)</p> <p>(follow‐up: 1 month to 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean plasma ammonia concentration (final and change scores) (μmol/L) in the intervention group was 8.29 fewer (13.17 fewer to 3.41 fewer). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>705<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious concerns or two levels for very serious concerns of imprecision (based on few events and wide confidence intervals).<br/><sup>2</sup>Downgraded one level for serious concerns or two levels for very serious concerns of trials judged as at high risk of bias (most studies at high risk of bias).<br/><sup>3</sup>Downgraded one level for serious concerns or two levels for very serious concerns of inconsistency of the outcomes in effects. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Probiotic for people with hepatic encephalopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008716-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Probiotics for people with hepatic encephalopathy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotic versus lactulose for people with hepatic encephalopathy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with hepatic encephalopathy<br/><b>Setting:</b> inpatients<br/><b>Intervention:</b> probiotic<br/><b>Comparison:</b> lactulose </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lactulose</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with probiotic</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>(follow‐up: 1 month to 2 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.00<br/>(0.25 to 102.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>200<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No‐recovery (incomplete resolution of clinical symptoms)</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.01<br/>(0.85 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>430<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>521 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>526 per 1000<br/>(443 to 630) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>505 per 1000<br/>(425 to 605) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events ‐ Overt hepatic encephalopathy</p> <p>(follow‐up: 1 to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.17<br/>(0.63 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>420<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000<br/>(51 to 177) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1000<br/>(38 to 129) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events ‐ Change of/or withdrawal from treatment</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.27<br/>(0.88 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>490<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000<br/>(141 to 291) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000<br/>(101 to 208) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>It is uncertain whether probiotics improve quality of life because the available evidence is of very low quality. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma ammonia concentration (final and change scores) (μmol/L)</p> <p>(follow‐up: 1 month to 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean plasma ammonia concentration (final and change scores) (μmol/L) in the intervention group was 2.93 fewer (9.36 fewer to 3.5 more). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one for serious concerns or two levels for very serious concerns of imprecision (small samples, very few events, and wide confidence intervals).<br/><sup>2</sup>Downgraded one level for serious concerns or two levels for very serious concerns of trials judged as at high risk of bias (majority of studies at high risk of bias).<br/><sup>3</sup>Downgraded one level for serious imprecision (95% CI includes null effects).<br/><sup>4</sup>Downgraded one level for serious concerns or two levels for very serious concerns of inconsistency in results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Probiotics for people with hepatic encephalopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008716-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of probiotics used across studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Probiotics used</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0001" title="BajajJS , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , HoffmannRG , et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week2007;132(4):A800. BajajJS , SaeianK , ChristensenKM , HafeezullahM , VarmaRR , FrancoJ , et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology2008;103(7):1707-15. McGeeR . Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. ">Bajaj 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Streptococcus thermophilus</i> , <i>Lactobacillus bulgaricus</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus casei</i> , <i>Bifidobacteria</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0002" title="BajajJS , HeumanD , HylemonP , SanyalA , SterlingR , StravitzR , et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology2014;1:S221. [0168-8278]BajajJS , HeumanDM , HylemonPB , SanyalAJ , PuriP , SterlingRK , et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1113-25. [0269-2813]">Bajaj 2014a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus</i> GG AT strain 53103 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0003" title="DhimanR , KhatriA , RanaS , ChopraM , ThumburuK , MalhotraS , et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology2013;28:401-2. [0815-9319]">Dhiman 2013a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VSL#3 (containing <i>Bifidobacterium breve</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus bulgaricus</i> , <i>Streptococcus thermophilus</i>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0004" title="LiuQ , DuanZP , HaDK , BengmarkS , KurtovicJ , RiordanSM . Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.)2004;39(5):1441-9. ">Liu 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Pediacoccus pentosaceus</i> , <i>Leuconostoc mesenteroides</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus plantarum</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0005" title="LoguercioC , Del Vecchio BlancoC , ColtortiM . Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research1987;15(6):335-43. McGeeR . Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. ">Loguercio 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Enterococcus</i> lactic acid bacteria strain SF68 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0006" title="LoguercioC , AbbiatiR , RinaldiM , RomanoA , Del Vecchio BlancoC , ColtortiM . Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology1995;23(1):39-46. [0168-8278: (Print)] ">Loguercio 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Enterococcus faecium</i> strain SF68 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0007" title="LuniaMK , SharmaBC , SrivastavS , SachdevaS . Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology2014;1:S246. [0168-8278]">Lunia 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VSL#3 (containing <i>Streptococcus thermophilus</i> , <i>Bifidobacterium breve</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus bulgaricus</i>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0008" title="MalaguarneraM , GarganteMP , MalaguarneraG , SalmeriM , MastrojeniS , RampelloL , et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2010;22(2):199-206. ">Malaguarnera 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Bifidobacterium</i> (subtype not available) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0009" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. MittalVV , SharmaBC , SharmaP , SarinSK . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2011;23(8):725-32. [0954-691X]MittalVV , SharmaP , SharmaB , SarinSK . Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.)2009;4 (Suppl):471A. ">Mittal 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VSL#3 (containing <i>Streptococcus thermophilus</i> , <i>Bifidobacterium breve</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus bulgaricus</i>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0010" title="MouliVP , BenjaminJ , Bhushan SinghM , ManiK , GargSK , SarayaA , et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research2015;45(8):880-9. [1872-034X]">Mouli 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VSL#3 (4 strains of <i>Lactobacillus</i> (<i>L acidophilus</i> DSM 24735, <i>L plantarum</i> DSM 24730, <i>L paracasei</i> DSM 24733, <i>L delbrueckii</i> subsp. <i>bulgaricus</i> DSM 24734), 3 strains of <i>Bifidobacterium</i> (<i>B longum</i> DSM 24736, <i>B breve</i> DSM 24732, <i>B infantis</i> DSM 24737), and 1 strain of <i>Streptococcus</i> (<i>S thermophilus</i> DSM 24731)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0011" title="DalalR . Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. NairRR . Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology2011;76(9):A222-3. [0028-3878]NairRRS , AbdurahimanP , JoseJ , SebastianS , ThomasV , GirijaA . Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology2008;70(11):A50. NairRRS , JoseJ , ThomasV . BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology2009;66:S28-9. [0364-5134]">Nair 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus acidophilus</i> , <i>Lactobacillus rhamnosus</i> , <i>Bifidobacterium longum</i> , <i>Saccharomyces boulardii</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0012" title="PeregD , KotliroffA , GadothN , HadaryR , LishnerM , Kitay-CohenY . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition2011;27(2):177-81. ">Pereg 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium bifidum</i> , <i>Streptococcus thermophilus</i> (Bio Plus, Supherb, Israel) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0013" title="Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology2010;22(2):105-6. ">Qiao 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bifid triple viable (not further specified)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0014" title="SajiS , KumarS , ThomasV . A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology2011;32(2):128-32. [0250-636X]">Saji 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus acidophilus</i> , <i>Lactobacillus rhamnosus</i> , <i>Bifidobacterium longum</i> , <i>Saccharomyces boulardii</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0015" title="McGeeR . Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. SharmaP , SharmaBC , PuriV , SarinSK . An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology &amp; Hepatology2008;20(6):506-11. SharmaP , SharmaBC , PuriV , SarinSK . A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. In: 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. Vol. 101. American College of Gastroenterology, 2006:402. ">Sharma 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Enterococcus faecalis</i> , <i>Clostridium butyricum</i> , <i>Bacillus mesentricus</i> , lactic acid <i>Bacillus</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0016" title="PantS , DwivediM , MisraSP , NarangS , SharmaK . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology2011;1:A51. [0254-8860]PantS , SharmaK , MisraSP , DwivediM , NarangS , MishraK , et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology2013;1:A92. [0254-8860]SharmaK , PantS , DwivediM , MisraSP , MisraA , NarangS . Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology2012;27:275-6. [0815-9319]SharmaK , PantS , MisraS , DwivediM , MisraA , NarangS , et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology2014;20(4):225-32. [1319-3767]">Sharma 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Velgut ERIS Pharmaceuticals, Ahmadabad, India (<i>Lactobacillus acidophilus</i> , <i>Lactobacillus rhamnosus</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus casei</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> , <i>Bifidobacterium breve</i> , <i>Saccharomyces boulardii</i> , <i>Streptococcus thermophilus</i>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0017" title="ShavakhiA , HashemiH , TabeshE , DerakhshanZ , FarzamniaS , MeshkinfarS , et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences2014;19(8):703-8. [1735-7136]">Shavakhi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Balance (Protexin Co., Somerset, UK) <i>Lactobacillus</i> strains (<i>L casei</i> , <i>L rhamnosus</i> , <i>L acidophilus</i> , <i>L bulgaricus</i> ), <i>Bifidobacterium</i> strains (<i>B breve</i> , <i>B longum)</i> , and <i>Streptococcus thermophilus</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0018" title="VlachogiannakosJ , VasianopoulouP , ViazisN , ChroniM , KaramanolisD , LadasSD . Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology2016;64(Suppl 2):S165. [1600-0641]VlachogiannakosJ , VasianopoulouP , Via-zisN , ChroniM , VoulgarisT , LadasSD , et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.)2014;60(4 Suppl):376A. ">Vlachogiannakos 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus plantarum</i> 299v </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0019" title="Zhao X-H, FengQ , ZhangJ , Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine2013;10(4):61-3. ">Zhao 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0020" title="ZhitaiZ . Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology2013;28:851. [0815-9319]">Zhitai 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live <i>Bacillus cereus</i> capsules </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008716-bbs2-0021" title="ZiadaDH , SolimanHH , YamanySA , HamisaMF , HasanAM . Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology2013;14(3):116-22. ">Ziada 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lactobacillus acidophilus</i> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of probiotics used across studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008716-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heterogeneity subgroup analysis</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Probiotic versus placebo or no intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No‐recovery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect estimate</b> </p> <p><b>Risk ratio [95% CI]</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference P</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Type of probiotic</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactobacillus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 [0.45, 1.00]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 [0.50, 0.83]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76 [0.58, 0.98]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Grade of hepatic encephalopathy</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 [0.52, 0.76]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 [0.64, 1.48]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Duration of therapy</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt;= 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 [0.58, 0.96]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 &gt; 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 [0.38, 1.10]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 + months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 [0.43, 0.78]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Co‐interventions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 [0.52, 0.76]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bioactive fermentable fibre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 [0.54, 1.86]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactulose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 [0.55, 1.69]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Plasma ammonia concentration</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect estimate</b> </p> <p><b>Mean difference [95% CI]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference P</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Type of probiotic</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bifidobacterium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.35 [‐16.09, ‐2.61]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactobacillus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.90 [‐24.41, 0.60]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.80 [‐9.65, 6.06]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐17.02 [‐44.07, 10.02]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Grade of hepatic encephalopathy</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.50 [‐14.38, ‐2.62]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.35 [‐16.09, ‐2.61]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Duration of therapy</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt;=1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.93 [‐12.25, 0.39]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 &gt; 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.11 [‐14.56, 4.34]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 + months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐18.53 [‐42.32, 5.26]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Co‐interventions used</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10.42 [‐18.68, ‐2.17]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bioactive fermentable fibre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.90 [‐5.51, ‐0.29]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactulose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7.88 [‐14.29, ‐1.47]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Probiotic versus lactulose</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Plasma ammonia concentration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect estimate</b> </p> <p><b>Mean difference [95% CI]</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference P</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Type of probiotic</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enterococcus SF68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.83 [‐24.51, ‐1.15]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34 [‐1.72, 4.40]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactobacillus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.17 [‐17.17, 10.83]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.31 [‐5.70, 8.32]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Grade of hepatic encephalopathy</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.16 [‐1.59, 3.91]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overt</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.83 [‐24.51, ‐1.15]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heterogeneity subgroup analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/full#CD008716-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008716-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Probiotic versus placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.23, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.11, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.19, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 No recovery (incomplete resolution of clinical symptoms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.56, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.58, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.38, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.43, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Overt hepatic encephalopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.16, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.11, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Intolerance leading to discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 Change of/or withdrawal from treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.46, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 SF‐36 Physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐5.47, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 SF‐36 Mental</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐9.82, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Change in Total SIP Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.66 [‐7.75, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Change in SIP Psychological Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.54 [‐4.95, ‐2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 Change in SIP Physical Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.94 [‐4.44, ‐1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Plasma ammonia concentration (final and change scores) (μmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.29 [‐13.17, ‐3.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.55 [‐10.67, ‐0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.11 [‐14.56, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.79 [‐10.39, ‐3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐31.08 [‐40.50, ‐21.66]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Probiotic versus placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008716-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Probiotic versus lactulose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 102.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 102.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 No recovery (incomplete resolution of clinical symptoms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.85, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 1 month or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.75, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.65, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.85, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Overt hepatic encephalopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.63, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 Intolerance leading to discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.08, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.5 Change of/or withdrawal from treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.88, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Change in Total SIP Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [‐1.13, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Change in SIP Psychological Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [‐1.04, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Change in SIP Physical Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [‐0.61, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Plasma ammonia concentration (final and change scores) (μmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.93 [‐9.36, 3.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 1 month or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.30 [‐13.17, 4.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [‐1.96, 4.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Probiotic versus lactulose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008716.pub3/references#CD008716-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008716.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008716-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008716-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008716-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD008716-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD008716-note-0009">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD008716-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008716-note-0012">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD008716-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008716-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008716\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008716\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008716\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008716\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008716\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008716.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008716.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008716.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008716.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008716.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715429261"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008716.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715429268"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008716.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d86de6f179374',t:'MTc0MDcxNTQyOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 